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A B S T R A C T
Background
Observational studies suggest higher pregnancy rates after the hysteroscopic removal of endometrial polyps, submucous fibroids, uterine
septum or intrauterine adhesions, which are detectable in 10% to 15% of women seeking treatment for subfertility.
Objectives
To assess the effects of the hysteroscopic removal of endometrial polyps, submucous fibroids, uterine septum or intrauterine adhesions
suspected on ultrasound, hysterosalpingography, diagnostic hysteroscopy or any combination of thesemethods inwomenwith otherwise
unexplained subfertility or prior to intrauterine insemination (IUI), in vitro fertilisation (IVF) or intracytoplasmic sperm injection
(ICSI).
Search methods
We searched the Cochrane Menstrual Disorders and Subfertility Specialised Register (6 August 2012), the Cochrane Central Register
of Controlled Trials (T he Cochrane Library 2012, Issue 7), MEDLINE (1950 to October 2012), EMBASE (1974 to October 2012),
CINAHL (from inception to October 2012) and other electronic sources of trials including trial registers, sources of unpublished
literature and reference lists. We handsearched the American Society for Reproductive Medicine (ASRM) conference abstracts and
proceedings (from January 2008 to October 2012) and we contacted experts in the field.
Selection criteria
Randomised comparisons between operative hysteroscopy versus control in women with otherwise unexplained subfertility or under-
going IUI, IVF or ICSI and suspected major uterine cavity abnormalities diagnosed by ultrasonography, saline infusion/gel instillation
sonography, hysterosalpingography, diagnostic hysteroscopy or any combination of these methods. Primary outcomes were live birth
and hysteroscopy complications. Secondary outcomes were pregnancy and miscarriage.
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Data collection and analysis
Two authors independently assessed studies for inclusion and risk of bias, and extracted data. We contacted study authors for additional
information.
Main results
Two studies met the inclusion criteria and neither reported the primary outcomes of live birth and complications from the procedure. In
women with otherwise unexplained subfertility and submucous fibroids, there is no evidence of benefit with hysteroscopicmyomectomy
compared to regular fertility-oriented intercourse during 12 months for clinical pregnancy (odds ratio (OR) 2.4, 95% confidence
interval (CI) 0.97 to 6.2, P = 0.06, 94 women) and miscarriage (OR 1.5, 95% CI 0.47 to 5.0, P = 0.47, 94 women) (very low-quality
evidence). The hysteroscopic removal of polyps prior to IUI increases the odds of clinical pregnancy (experimental event rate (EER)
63%) compared to diagnostic hysteroscopy and polyp biopsy only (control event rate (CER) 28%) (OR 4.4, 95% CI 2.5 to 8.0, P <
0.00001, 204 women, high-quality evidence).
Authors’ conclusions
Hysteroscopic myomectomy might increase the odds of clinical pregnancy in women with unexplained subfertility and submucous
fibroids, but the evidence is at present not conclusive. The hysteroscopic removal of endometrial polyps suspected on ultrasound in
women prior to IUI might increase the clinical pregnancy rate. More randomised studies are needed to substantiate the effectiveness of
the hysteroscopic removal of suspected endometrial polyps, submucous fibroids, uterine septum or intrauterine adhesions in women
with unexplained subfertility or prior to IUI, IVF or ICSI.
P L A I N L A N G U A G E S U M M A R Y
Hysteroscopy for treating suspected abnormalities of the cavity of the womb in women having difficulty becoming pregnant
Human life starts when a fertilised egg has successfully implanted in the inner layer of the cavity of the womb. It is believed that
abnormalities originating from this site, such as polyps, fibroids, septa or adhesions, may disturb this important event. The removal
of these abnormalities by doing a so-called hysteroscopy using a very small diameter inspecting device might therefore increase the
chance of becoming pregnant either spontaneously or after specialised fertility treatment, such as intrauterine insemination or in vitro
fertilisation. This review identified no studies reporting live birth as an outcome. We found one study on the removal of fibroids in
women with unexplained infertility. It suggests that there might be a higher chance of conceiving after surgery compared to regular
sexual intercourse for 12 months. Due to the low number of women (94) and the low number of pregnancies (30) the differences
are not statistically significant. The quality of the study is very low. Therefore uncertainty remains about the real value of removal of
fibroids in raising the chance of conception in women having difficulty becoming pregnant. We found only one study on hysteroscopy
in 215 women with polyps who were to be treated with insemination for various fertility problems. The findings support an important
increase in the pregnancy rates after the hysteroscopic removal of polyps. Although the quality of this study is high, further studies are
needed to confirm this result. Neither of the two studies reported data on the surgical complications of hysteroscopy.
More studies are needed before hysteroscopy can be proposed as a fertility-enhancing procedure in the general population of women
having difficulty becoming pregnant.
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B A C K G R O U N D
Description of the condition
Subfertility is “a disease of the reproductive system defined by
the failure to achieve a clinical pregnancy after 12 months or
more of regular unprotected sexual intercourse” according to
the International Committee for Monitoring Assisted Reproduc-
tive Technology (ICMART) and the World Health Organiza-
tion (WHO) revised glossary of assisted reproductive technology
(ART) (Zegers-Hochschild 2009). It is estimated that 72.4million
women are subfertile and that 40.5 million of these are currently
seeking fertility treatment (Boivin 2007). Unexplained subfertility
usually refers to a diagnosis (or lack of diagnosis) made in couples
in whom all the standard investigations such as tests of ovulation,
tubal patency and semen analysis are normal: it can be found in
as many as 30% to 40% of subfertile couples (Ray 2012).
The evaluation of the uterine cavity is a basic step in the investiga-
tion of subfertile women since the uterine cavity and its inner layer,
the endometrium, are assumed to be important for the implanta-
tion of the human embryo, called a blastocyst. Nevertheless, the
complex mechanisms leading to successful implantation are still
poorly understood (Taylor 2008). Despite the huge investment
in research and developments of the technologies and biology in-
volved in medically assisted reproduction (MAR), the maximum
implantation rate per embryo transferred still remains only 30%
(Andersen 2008). The different phases of the implantation process
are established by the complex interchange between the blastocyst
and the endometrium (Singh 2011).
Major uterine cavity abnormalities can be found in 10% to 15%
of women seeking treatment for subfertility; they usually consist
of the presence of excessive normal uterine tissue (Wallach 1972).
The most common acquired uterine cavity abnormality is an en-
dometrial polyp. This benign, endometrial stalk-like mass pro-
trudes into the uterine cavity and has its own vascular supply. De-
pending on the population under study and the applied diagnostic
test, endometrial polyps can be found in 1% to 41% of the subfer-
tile population (Silberstein 2006). A fibroid is an excessive growth
originating from the muscular part of the uterine cavity. Fibroids
are present in 2.4% of subfertile women without any other obvi-
ous cause of subfertility (Donnez 2002). A submucous fibroid is
located underneath the endometrium and is thought to interfere
with fertility by deforming the uterine cavity. Intrauterine adhe-
sions are fibrous tissue strings connecting parts of the uterine wall.
They are commonly caused by inflammation or iatrogenic tissue
damage (meaning involuntarily caused by a physician’s interven-
tion, for example an aspiration curettage after miscarriage) and
are present in 0.3% to 14% of subfertile women (Fatemi 2010).
A septate uterus is a congenital malformation in which the longi-
tudinal band separating the left and right Müllerian ducts, which
form the uterus in the human female fetus, has not been entirely
resorbed. A uterine septum is present in 1% to 3.6% of women
with otherwise unexplained subfertility (Saravelos 2008).
Ultrasonography (US), preferably transvaginally (TVS), is used
to screen for possible endometrium or uterine cavity abnormal-
ities in the work-up of subfertile patients. This evaluation can
be expanded with hysterosalpingography (HSG), saline infusion/
gel instillation sonography (SIS/GIS) and diagnostic hysteroscopy.
Diagnostic hysteroscopy is generally considered as being the gold
standard procedure for the assessment of the uterine cavity since
it enables direct visualisation; moreover, treatment of intrauterine
pathology can be done in the same setting (Bettocchi 2004). Nev-
ertheless, even for experienced gynaecologists the hysteroscopic
diagnosis of the major uterine cavity abnormalities may be prob-
lematic (Kasius 2011a).
Description of the intervention
Hysteroscopy is performed for the evaluation, or for the treat-
ment of the uterine cavity, tubal ostia and endocervical canal in
women with uterine bleeding disorders, Müllerian tract anoma-
lies, retained intrauterine contraceptives or other foreign bodies,
retained products of conception, desire for sterilisation, recurrent
miscarriage and subfertility. If the procedure is done for the pur-
pose of evaluating the uterine cavity only, it is called a diagnos-
tic hysteroscopy. If the observed pathology requires further treat-
ment, the procedure is called an operative hysteroscopy. In every-
day practice, a diagnostic hysteroscopy confirming the presence
of pathology will be followed by an operative hysteroscopy in a
symptomatic patient.
Hysteroscopy allows the direct visualisation of the uterine cavity
through a rigid, semi-rigid or flexible endoscope. The hystero-
scope consists of a rigid telescope with a proximal eyepiece and
a distal objective lens that may be angled at 0° to allow direct
viewing or offset at various angles to provide a fore-oblique view.
Advances in fibreoptic technology have led to the miniaturisation
of the telescopes without compromising the image quality. The
total working diameters of modern diagnostic hysteroscopes are
typically 2.5 to 4.0mm.Operative hysteroscopy requires adequate
visualisation through a continuous fluid circulation using an in-
and an outflow channel. The outer diameters of modern operative
hysteroscopes have been reduced to a diameter between 4.0 and
5.5 mm. The sheath system contains one or two 1.6 to 2.0 mm
working channels for the insertion of small grasping or biopsy for-
ceps, scissors, myoma fixation instruments, retraction loops, mor-
cellators and aspiration cannulae, or unipolar or bipolar electro-
diathermy instruments.
Most diagnostic and many operative procedures can be done in an
office setting using local anaesthesia and fluid distension media,
while more complex procedures are generally performed as day
surgery under general anaesthesia (Clark 2005). Operative hys-
teroscopic procedures require a complex instrumentation set-up,
special training of the surgeon and appropriate knowledge and
management of complications (Campo 1999).
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Although complications from hysteroscopy are rare, they may be
potentially life threatening. A multicentre study including 13,600
diagnostic and operative hysteroscopic procedures performed in
82 centres reported a complication rate of 0.28%. Diagnostic hys-
teroscopy had a significantly lower complication rate compared to
operative hysteroscopy (0.13% versus 0.95%). Themost common
complicationof both types of hysteroscopywas uterine perforation
(0.13% for diagnostic; 0.76% for operative hysteroscopy). Fluid
intravasation occurred almost exclusively in operative procedures
(0.02%). Intrauterine adhesiolysis was associated with the highest
incidence of complications (4.5%); all of the other procedures had
complication rates of less than 1% (Jansen 2000).
How the intervention might work
It is assumed thatmajor uterine cavity abnormalities interfere with
the factors that regulate the blastocyst-endometrium interplay, for
example hormones and cytokines, precluding the possibility of
pregnancy. Many hypotheses have been formulated in the litera-
ture of how endometrial polyps (Shokeir 2004; Silberstein 2006;
Taylor 2008; Yanaihara 2008), submucous fibroids (Pritts 2001;
Somigliana 2007; Taylor 2008), intrauterine adhesions (Yu 2008)
and uterine septum (Fedele 1996) are likely to disturb the implan-
tation of the human embryo; nevertheless, the precise mechanisms
of action through which each one of these major uterine cavity
abnormalities affects this essential reproductive process are poorly
understood.
For endometrial polyps, submucous fibroids, intrauterine adhe-
sions and uterine septum, observational studies have shown a clear
improvement in the spontaneous pregnancy rate after the hystero-
scopic removal of the abnormality (Taylor 2008). The chance for
pregnancy is significantly lower in subfertile women with submu-
cous fibroids compared to other causes of subfertility according
to a systematic review and meta-analysis of 11 observational stud-
ies (Pritts 2001; Pritts 2009). Three observational studies found
a major benefit for removing a uterine septum by hysteroscopic
metroplasty in subfertile women with a uterine septum (Mollo
2009; Shokeir 2011; Toma evi 2010).
Why it is important to do this review
A National Institute for Health and Clinical Excellence (NICE)
guideline on fertility assessment and treatment states that “women
should not be offered hysteroscopy on its own as part of the initial
investigation unless clinically indicated because the effectiveness
of surgical treatment of uterine abnormalities on improving preg-
nancy rates has not been established” (NICE 2004). There is, how-
ever, a trend in reproductive medicine that is developing towards
diagnosis and treatment of all major uterine cavity abnormalities
prior to fertility treatment. This evolution can be explained by
three reasons. Firstly, diagnostic hysteroscopy is generally accepted
in everyday clinical practice as the ‘gold standard’ for identifying
uterine abnormalities because it allows direct visualisation of the
uterine cavity (Golan 1996). Secondly, since 2004 several ran-
domised controlled trials (RCTs) have demonstrated the techni-
cal feasibility and the high patient satisfaction rate in women un-
dergoing both diagnostic and operative hysteroscopy for various
reasons including subfertility (Campo 2005; De Placido 2007;
Garbin 2006; Guida 2006; Kabli 2008; Marsh 2004; Sagiv 2006;
Shankar 2004; Sharma 2005). Thirdly, in a subfertile population
screened systematically by diagnostic hysteroscopy the incidence
of newly detected intrauterine pathology may be as high as 50%
(Campo 1999; De Placido 2007).
This review aims to summarise and critically appraise the cur-
rent evidence on the effectiveness of operative hysteroscopic in-
terventions in subfertile women with major uterine cavity abnor-
malities, both in women with unexplained subfertility and those
bound to undergo MAR. Since uterine cavity abnormalities might
negatively affect the uterine environment, and therefore the like-
lihood of conceiving (Rogers 1986), it has been recommended
that these abnormalities be diagnosed and treated by hysteroscopy
to improve the cost-effectiveness in subfertile women undergoing
MAR, where recurrent implantation failure is inevitably associated
with a higher economic burden to society.
The study of the association between subfertility and major uter-
ine cavity abnormalities might increase our current understanding
of the complex mechanisms of human embryo implantation. This
could lead to the development of cost-effective strategies in re-
productive medicine with benefits for both the individual woman
suffering from subfertility associated with major uterine cavity ab-
normalities as well as for society, in a broader perspective.
O B J E C T I V E S
To assess the effects of the hysteroscopic removal of endometrial
polyps, submucous fibroids, uterine septum or intrauterine adhe-
sions suspected on ultrasound, hysterosalpingography, diagnostic
hysteroscopy or any combination of thesemethods in women with
otherwise unexplained subfertility or prior to intrauterine insemi-
nation (IUI), in vitro fertilisation (IVF) or intracytoplasmic sperm
injection (ICSI).
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Inclusion criteria
• Only trials that were either clearly randomised or claimed
to be randomised and did not have evidence of inadequate
sequence generation such as date of birth or hospital number
were eligible for inclusion.
• Cluster trials were considered to be eligible if the
individually randomised women were the unit of analysis.
• Cross-over trials were also considered to be eligible for
completeness but we planned to use only pre- cross-over data for
meta-analysis.
Exclusion criteria
• Quasi-randomised trials.
Types of participants
Inclusion criteria
• Women of reproductive age with otherwise unexplained
subfertility and endometrial polyps, submucous fibroids, septate
uterus or intrauterine adhesions detected by US, SIS, GIS, HSG,
diagnostic hysteroscopy or any combination of these methods.
Besides unexplained subfertility as the prevailing clinical
problem, other gynaecological complaints, such as pain or
bleeding, might or might not be present.
• Women of reproductive age with subfertility, undergoing
IUI, IVF or ICSI with endometrial polyps, submucous fibroids,
septate uterus or intrauterine adhesions detected by US, SIS,
GIS, HSG, diagnostic hysteroscopy or any combination of these
methods.
Exclusion criteria
• Women of reproductive age with subfertility and
intrauterine cavity abnormalities other than endometrial polyps,
submucous fibroids, intrauterine adhesions and septate uterus,
e.g. subserous or intramural fibroids without cavity deformation
on hysteroscopy, acute or chronic endometritis, adenomyosis or
other so-called ’subtle focal’ lesions.
• Women of reproductive age with endometrial polyps,
submucous fibroids, intrauterine adhesions or septate uterus
without subfertility.
• Women of reproductive age with recurrent pregnancy loss.
Types of interventions
Two types of randomised interventions were addressed; within
both comparisons the suspected major uterine cavity abnormali-
ties were stratified into endometrial polyps, submucous fibroids,
uterine septum and intrauterine adhesions. For the second com-
parison there was a stratification into IUI, IVF or ICSI.
• Randomised comparison between operative hysteroscopy
versus control in women with otherwise unexplained subfertility
and suspected major uterine cavity abnormalities diagnosed by
US, SIS, GIS, HSG, diagnostic hysteroscopy or any combination
of these methods.
• Randomised comparison between operative hysteroscopy
versus control in women undergoing IUI, IVF or ICSI with
suspected major uterine cavity abnormalities diagnosed by US,
SIS, GIS, HSG, diagnostic hysteroscopy or any combination of
these methods.
Types of outcome measures
Primary outcomes
1. Effectiveness: live birth, defined as a delivery of a live fetus after
20 completed weeks of gestational age that resulted in at least one
live baby born. The delivery of a singleton, twin or multiple preg-
nancy was counted as one live birth (Zegers-Hochschild 2009).
2. Adverse events: hysteroscopy complications, defined as any
complication due to hysteroscopy.
Secondary outcomes
3. Pregnancy
• Ongoing pregnancy, defined as a pregnancy surpassing the
first trimester or 12 weeks of pregnancy.
• Clinical pregnancy with fetal heart beat, defined as a
pregnancy diagnosed by US or clinical documentation of at least
one fetus with a heart beat (Zegers-Hochschild 2009).
• Clinical pregnancy, defined as a pregnancy diagnosed by US
visualisation of one or more gestational sacs or definitive clinical
signs of pregnancy (Zegers-Hochschild 2009).
4. Adverse events: miscarriage, defined as the spontaneous loss of
a clinical pregnancy before 20 completed weeks of gestation, or if
gestational age is unknown a fetus with a weight of 500 g or less
(Zegers-Hochschild 2009).
We planned to report the minimally important clinical difference
(MICD) for the primary outcome of live birth. AMICD of 5% for
the live birth rate was predefined as being relevant for the benefits.
The imputation of this value was based on data from a clinical
decision analysis on screening hysteroscopy prior to IVF (Kasius
2011b).
We planned to include the main outcome measures ’live birth’,
’hysteroscopy complications’ and ’miscarriage’ in a ’Summary of
findings’ table (SoF). The SoF table was generated using GRADE-
pro software (GRADE profiler version 3.2.2). This table evaluated
the overall quality of the body of evidence for the main review
outcomes, using GRADE criteria (study limitations (i.e. risk of
bias), consistency of effect, imprecision, indirectness and publica-
tion bias).We justified, documented and incorporated judgements
about evidence quality (high, moderate, low or very low) into the
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reporting of results for each outcome (Summary of findings for
the main comparison; Summary of findings 2).
See the methods section of the protocol of this Cochrane review
published in the Cochrane Database of Systematic Reviews (Bosteels
2011).
Search methods for identification of studies
See the Cochrane Menstrual Disorders and Subfertility Group
(MDSG) for methods used in reviews, as stated in the MDSG
Module.
See also the methods section of the protocol for this Cochrane
review published in the Cochrane Database of Systematic Reviews
(Bosteels 2011).
An experienced librarian at the Biomedical Library Gasthuisberg
of the Catholic University of Leuven (Jens De Groot) developed
the literature search strategy in liaison with the MDSG Trials
Search Co-ordinator (Marian Showell).
Two people (JB and JK) independently performed a comprehen-
sive search of all published and unpublished reports that described
hysteroscopy in subfertile women with endometrial polyps, sub-
mucous fibroids, intrauterine adhesions or septate uterus, or un-
dergoing MAR. The search strategy was not limited by language,
year of publication or document format. All the retrieved citations
fromMEDLINE, EMBASE, WoS, CENTRAL, the MDSG Spe-
cialised Register, BIOSIS PREVIEWS and handsearch-related ar-
ticles have been merged and duplicates have been removed using
specialised software (EndNote Web 3.5 - last done on 28 October
2012).
Electronic searches
We searched the following bibliographic databases, trial registers
and websites: the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2012, Issue 7) (Appendix 1),
the Menstrual Disorders and Subfertility Group (MDSG) Spe-
cialised Register (Appendix 2), MEDLINE using PubMed (1950
to 27 October 2012) (Appendix 3) and EMBASE using EM-
BASE.com (1974 to 27 October 2012) (Appendix 4).
The search strategy combined both index and free-text terms.
Our MEDLINE search included the Cochrane highly sensitive
search strategy for identifying randomised trials using the PubMed
format which appears in the Cochrane Handbook for Systematic
Reviews of Interventions (version 5.1.0, Chapter 6, 6.4.11.1 - box
6.4.a) (Higgins 2011).
Our EMBASE search included the SIGN trial filter developed by
the Scottish Intercollegiate Guidelines Network (www.sign.ac.uk/
methodology/filters.html#random).
Other electronic sources of trials were:
• Cochrane Database of Systematic Reviews (CDSR) in The
Cochrane Library 2012, Issue 8 for published reviews to check for
references to the included and excluded studies.
• Database of Abstracts of Reviews of Effectiveness (DARE)
and the Health Technology Assessment Database (HTA
Database) through the Centre for Reviews and Dissemination
(from inception to 28 October 2012) (www.crd.york.ac.uk).
• National Guideline Clearinghouse (www.guideline.gov) for
evidence-based guidelines (from inception to 28 October 2012).
• BIOSIS previews through ISI Web of Knowledge (http://
isiwebofknowledge.com) and CINAHL (www.cinahl.com)
through EBSCOHOST available at the Biomedical Library
Gasthuisberg of the Catholic University of Leuven (from
inception to 27 October 2012) (Appendix 5).
• Trial registers for ongoing and registered trials: ’Current
Controlled Trials’ (www.controlled-trials.com),
’ClinicalTrials.gov’ provided by the US National Institutes of
Health (http://clinicaltrials.gov/ct2/home) and the World
Health Organization International Clinical Trials Registry
Platform search portal (http://apps.who.int/trialsearch/) (from
inception to 28 October 2012).
• Citation indexes: Science Citation Index through Web of
Science (http://scientific.thomson.com/products/sci/) - SCI-
EXPANDED (1955 to 27 October 2012) and Conference
Proceedings Citation Index - Science (CPCI-S) (1990 to 27
October 2012) and Scopus (http://www.info.sciverse.com/
scopus/) (from inception to 27 October 2012).
• Conference abstracts and proceedings on the ISI Web of
Knowledge (http://isiwebofknowledge.com) applying ’SCI-
EXPANDED’ (1955 to 27 October 2012) and ’CPCI-S’ (1990
to 27 October 2012) (Appendix 6).
• LILACS database, which is a source of trials from the
Spanish and Portuguese speaking world (http://bases.bireme.br/
cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&
base=LILACS&lang=i&form=F) (from inception to 28 October
2012).
• European grey literature through Open Grey database
(from inception to 28 October 2012) (http://www.opengrey.eu/
subjects/).
• General search engines: Turning Research into Practice
(TRIP) database (www.tripdatabase.com), Google Scholar (
http://scholar.google.be/advanced_scholar_search) and Scirus (
http://www.scirus.com) (from inception to 28 October 2012).
Searching other resources
Twopeople (JB and JK) independently handsearched the reference
lists of reviews, guidelines, included and excluded studies andother
related articles for additional eligible studies. JB contacted the first
or corresponding authors of included studies to ascertain if they
were aware of any ongoing or unpublished trials.
We handsearched the American Society for Reproductive
Medicine (ASRM) conference abstracts and proceedings (from
2008 to 30 October 2012) independently (JB and JK) since these
were not covered in the MDSG register (after consultation with
the MDSG Trials Search Co-ordinator).
8Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
JB contacted European experts and opinion leaders in the field of
hysteroscopic surgery through a formalised project approved by
the Board of the European Society of Gynaecological Endoscopy
(ESGE) to ascertain if these experts were aware of any relevant
published or unpublished studies.
Data collection and analysis
Selection of studies
Two people were responsible for independently selecting the stud-
ies (FB and TD). We scanned titles and abstracts from the searches
and obtained the full text of those articles that appeared to be eli-
gible for inclusion. We linked multiple reports of the same study
together while citing all the references and indicating the pri-
mary reference of the identified study. On assessment we cate-
gorised the trials as ’included studies’ (Characteristics of included
studies), ’excluded studies’ (Characteristics of excluded studies),
’ongoing studies’ (Characteristics of ongoing studies) studies or
’studies awaiting classification’ (Characteristics of studies awaiting
classification). Any disagreements between both review authors
who are content experts were resolved through consensus or by
a third review author with methodological expertise (BWM). We
contacted the first or corresponding authors of the primary study
reports for further clarification when required. If disagreements
between review authors were not resolved, we categorised the stud-
ies as ’awaiting classification’ and the disagreement was reported
in the final review. We avoided the exclusion of studies on the
basis of the reported outcome measures throughout the selection
phase by searching all potential eligible studies that could have
measured the primary or secondary outcomes even if these were
not reported. We appraised studies in an unblinded fashion, as
recommended by the Cochrane Menstrual Disorders and Subfer-
tility Review Group.
Data extraction and management
Two people, one methodologist (JB) and one topic area specialist
(SW), independently assessed the studies that appeared to meet
the inclusion criteria by using data extraction forms based on the
items listed in appendix 7 of the Cochrane protocol (Appendix
7). We pilot-tested the data extraction form and process by re-
viewing 10 randomly chosen reports of studies. In the pilot phase
one retracted study report (Shokeir 2011) was consistently iden-
tified by the two review authors on the basis of finding duplicated
parts from another study included in the present Cochrane review
(Pérez-Medina 2005). For studies with multiple publications, we
used themain trial report as the primary data extraction source and
additional details supplemented from secondary papers if appli-
cable. JB contacted the first or corresponding authors of the orig-
inal studies to obtain clarification whenever additional informa-
tion on trial methodology or original trial data was required. We
sent reminder correspondence if a reply was not obtained within
two weeks. The two review authors resolved any discrepancies in
opinion by discussion; they searched for arbitration by a third re-
view author if consensus was not reached (BWM). BWM resolved
disagreements which could not be resolved by the review authors
after contacting the first or corresponding authors of the primary
study reports. If this failed, the disagreement was reported in the
review.
Assessment of risk of bias in included studies
Two authors (JB and SW) independently assessed the risk of bias
of the included studies by using the Cochrane ’Risk of bias’ as-
sessment tool that considers the following criteria, listed in the
Cochrane Handbook for Systematic Reviews of Interventions (version
5.1.0, Chapter 8, table 8.5.a and 8.5.b) (Higgins 2011): random
sequence generation; allocation concealment; blinding of partic-
ipants and personnel; blinding of outcome assessors; complete-
ness of outcome data; selective outcome reporting; other potential
sources of bias. As pre-specified and explained in the published
protocol for this review (Bosteels 2011) the criteria ’blinding of
participants and personnel’ and ’blinding of outcome assessors’
were not included in the ’Risk of bias’ assessment. We justify this
for the following two reasons. Blindness to whether an operative or
diagnostic hysteroscopy was carried out in a trial is never possible
for the surgeon; given the legal obligation to obtain fully informed
consent before a surgical intervention, blinding of the patient is
hardly possible in daily practice. Moreover, by selecting only ’hard
outcomes’ which are easy to ascertain, even unblinded observers
of a given study participant are unlikely to disagree about whether
or not these outcomes have occurred. Lack of blinding will not
increase the risk of bias if follow-up is complete and outcomes
are unequivocal (e.g. live birth). JB and SW assessed therefore
only four of the six criteria in the Cochrane ’Risk of bias’ tool;
any disagreements were resolved by consensus or by discussion
with a third review author (BWM). We fully described all judge-
ments. The conclusions were presented in the ’Risk of bias’ table
(Characteristics of included studies) and incorporated into the in-
terpretation of review findings by means of sensitivity analyses.
We presented a narrative description of the quality of evidence
which is necessary for the interpretation of the results of the review
and which is based on the review authors’ judgements on the risk
of bias of the included trials (Quality of the evidence).
Measures of treatment effect
For the dichotomous data for live birth, pregnancy,miscarriage and
hysteroscopy complications we used the numbers of events in the
control and intervention groups of each study to calculateMantel-
Haenszel (M-H) odds ratios (OR). We presented 95% confidence
intervals (95% CI) for all outcomes. The OR has mathematically
sound properties that are consistent with benefit or harm and
which work well inmost RCTs on the effectiveness of reproductive
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surgery given that sample sizes are usually small and trial events are
rare. Where data to calculate ORs were not available, we planned
to utilise the most detailed numerical data available that might
facilitate similar analyses of included studies (e.g. test statistics, P
values). We have compared the magnitude and direction of effect
reported by studies with how they were presented in the review,
taking account of legitimate differences. We contacted the corre-
sponding or first authors of all included trials that reported data
in a form that was not suitable for meta-analysis, such as time-to-
pregnancy data (TTP). We planned reporting the data of those
reports that failed to present additional data that could be analysed
under ’other data’; we have not included TTP data in any meta-
analysis.
Unit of analysis issues
All primary and secondary outcomes were expressed as per woman
randomised. We planned to summarise reported data that did
not allow a valid analysis, such as ’per cycle’, in an additional
table without any attempt at meta-analysis. Multiple live births
and multiple pregnancies were counted as one live birth or one
pregnancy event.We planned including only first-phase data from
cross-over trials, if available.
Dealing with missing data
We aimed to analyse the data on an intention-to-treat basis. We
tried to obtain as much missing data as possible from the original
investigators. If this was not possible, we undertook imputation
of individual values for the primary outcomes only. We assumed
that live births would not have occurred in participants without
a reported primary outcome. For all other outcomes we analysed
only the available data. We subjected any imputation of missing
data for the primary outcomes to sensitivity analysis. If substantial
differences in the analysis were found as compared to an available
data analysis, we reported this in the final review.
Assessment of heterogeneity
We planned to consider whether the clinical and methodological
characteristics of the included studies were sufficiently similar for
meta-analysis to provide a clinically meaningful summary, if more
randomised studies were included. We planned to carry out a for-
mal assessment of statistical heterogeneity by using the I² statistic
combined with the Q-statistic. Cochran’s Q test, a kind of Chi²
statistic, is the classical measure to test significant heterogeneity.
Cochran’s Q test is calculated as the weighted sum of squared dif-
ferences between individual study effects and the pooled effect
across studies. The Q-statistic follows Chi² distribution with k-
1 degree of freedom where k is the number of studies. Q > k-1
suggests statistical heterogeneity. A low P value of Cochran’s Q test
means significant heterogeneous results among different studies;
usually, the P value at 0.10 is used as the cut-off. The Q-statistic
has low power as a comprehensive test of heterogeneity especially
when the number of studies is small. The Q-statistic informs us
about the presence or absence of heterogeneity; it does not report
on the extent of such heterogeneity. The I² statistic describes the
percentage of variation across studies that is due to significant het-
erogeneity rather than random chance. It measures the extent of
heterogeneity. An I² statistic greater than 50% was taken to indi-
cate substantial heterogeneity (Higgins 2003). We planned to ex-
plore possible explanations for heterogeneity by performing sensi-
tivity analyses in RevMan 5 (RevMan 2011), if there was evidence
of substantial statistical heterogeneity.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication
bias, reporting bias and within-study reporting bias, we planned
to minimise their potential impact by ensuring a comprehensive
search for eligible studies and by being alert in identifying dupli-
cation of data. We aimed to detect within-trial selective reporting
bias, such as trials failing to report obvious outcomes, or reporting
them in insufficient detail to allow inclusion. We planned to seek
published protocols and to compare the outcomes between the
protocol and the final published study report. Where identified
studies failed to report the primary outcomes (e.g. live birth), but
did report interim outcomes (e.g. pregnancy), we would have un-
dertaken informal assessment as towhether the interim values were
similar to those reported in studies that also reported the primary
outcomes. If there were outcomes defined in the protocol or the
study report with insufficient data to allow inclusion, the review
indicated this lack of data and suggested that further clinical trials
need to be conducted to clarify these knowledge gaps. If there were
10 or more studies, we planned to create a funnel plot to explore
the possibility of small study effects (a tendency for estimates of
the intervention effect to be more beneficial in smaller studies). A
gap on either side of the graph would have given a visual indication
that some trials had not been identified. Given the low number
of studies included in the final review, it was not possible to assess
reporting bias formally.
Data synthesis
JB entered the data and carried out the statistical analysis of the
data using Review Manager 5 software (RevMan 5). We consid-
ered the outcomes live birth and pregnancy to be positive and
higher numbers as a benefit. We considered the outcomes miscar-
riage and hysteroscopy complications in the protocol as negative
effects and higher numbers harmful. These aspects were taken into
consideration when assessing the summary graphs. In the quan-
titative synthesis an increase in the odds of a particular outcome,
either beneficial or harmful, was displayed graphically to the right
of the centre-line and a decrease in the odds of an outcome to the
left of the centre-line.
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We planned to combine data from primary studies in a meta-
analysis with RevMan 5 using the Peto method and a fixed-effect
model (Higgins 2011) for the following comparisons, if more ran-
domised studies could have been included and if significant clin-
ical diversity and statistical heterogeneity could have been confi-
dently ruled out:
• Operative hysteroscopy versus control in women with
otherwise unexplained subfertility and suspected major uterine
cavity abnormalities diagnosed by US, SIS, GIS, HSG,
diagnostic hysteroscopy or any combination of these methods.
• Operative hysteroscopy versus control in women
undergoing MAR with suspected major uterine cavity
abnormalities diagnosed by US, SIS, GIS, HSG, diagnostic
hysteroscopy or any combination of these methods.
We planned to define analyses that were both comprehensive and
mutually exclusive so that all eligible study results were slotted
into one stratum only. If no trials were retrieved for some com-
parisons, the review indicated their absence identifying knowledge
gaps which need further research. Sincemeta-analysis was not pos-
sible due to the limited number of studies included in the review,
we presented a narrative overview as pre-specified in the protocol
(Bosteels 2011).
Subgroup analysis and investigation of heterogeneity
We planned to carry out subgroup analyses to determine the sepa-
rate evidence within the following subgroups, if enough data were
available.
• Those studies that reported ’live birth’ and ’ongoing or
clinical pregnancy’ in order to assess any overestimation of effect
and reporting bias.
• For the two types of randomised comparison, stratified
according to the type of uterine abnormality, we planned to carry
out subgroup analyses according to the extent or severity of the
uterine abnormality. We used the length and diameter in
centimetres or calculated volumes of endometrial polyps and
submucous fibroids, the lengths and widths of uterine septa and
the European Society of Gynaecological Endoscopy (ESGE)
classification for intrauterine adhesions (Wamsteker 1998) as
references when applicable.
• We planned to carry out subgroup analyses based on the
patient age if enough studies were available.
The interpretation of the statistical analysis for subgroups is not
without problems. In the final review we reported the interpreta-
tion of any subgroup analysis performed restrictively, if at all pos-
sible, and with utmost caution even if enough data were retrieved.
Sensitivity analysis
We performed sensitivity analyses for the primary outcomes to
determine whether the conclusions are robust to arbitrary deci-
sions made regarding the eligibility and analysis. These analyses
included consideration of whether conclusions would have dif-
fered if:
• eligibility were restricted to studies without high risk of bias;
• alternative imputation strategies were adopted;
• a random-effects rather than a fixed-effect model was
adopted;
• the summary effect measure was risk ratio rather than odds
ratio.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
JB and JK scanned the titles and abstracts of the results of the
search strings. TheCENTRAL search produced 22 abstracts; there
were 155 abstracts from the MDSG Specialised Register, 69 from
MEDLINE, 248 from EMBASE, 210 from BIOSIS PREVIEWS
and 60 from ISI Web of Science. An electronic search in DARE
produced four abstracts; there was one guideline from National
Guideline Clearinghouse, six from the metaRegister of controlled
trials, eight from WHO ICTRP and 139 from TRIP/Google
Scholar/Scirus. We identified 77 additional references in Scopus.
No additional references were retrieved in CINAHL, LILACS and
OpenGrey. From handsearching reference lists and related articles
793 abstracts were identified. The handsearch of the proceedings
of the American Society for Reproductive Medicine produced 21
abstracts; two abstracts were identified after contacting the experts
of the European Society for Gynaecological Endoscopy (ESGE).
We assessed one non-English language trial for inclusion (Trnini -
Pjevi 2011). An English translation of the summary of the Ser-
bian abstract was available, suggesting that the study is a clinical
controlled trial but it is not certain whether a random sequence
generation was used or not. Since no further clarification could
be obtained from the authors of the study we categorised this
trial as ’awaiting classification’ (Characteristics of studies awaiting
classification).
After combining 3024 records identified from electronic searches
with 816 additional records through searching other sources, we
screened 3840 records for duplicates by using a specialised soft-
ware program (EndNote Web 3.5). After the removal of 2161 du-
plicate references, we screened 1679 records through titles and/
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or abstracts; 1590 records were excluded as being obviously ir-
relevant. We assessed 89 full-text articles for eligibility: 59 full-
text articles were excluded because they presented data from ob-
servational studies or were narrative reviews. The remaining full-
text articles identified 30 randomised controlled trials on hystero-
scopic interventions in subfertile women; only two studies were
included (Characteristics of included studies), 20 were excluded
(Characteristics of excluded studies), two are awaiting classifica-
tion (Characteristics of studies awaiting classification) and six are
ongoing (Characteristics of ongoing studies).
See: PRISMA flow chart (Figure 1).
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Figure 1. PRISMA study flow diagram.
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Included studies
Study design and setting
Two parallel-design randomised controlled trials were included in
the review.
Both were single-centre studies, one conducted in Italy (Casini
2006) and the other in Spain (Pérez-Medina 2005).
Participants
One study (Casini 2006) included 94 women with submucous
fibroids and otherwise unexplained subfertility. There were 52
women in the intervention group and 42 women in the control
group. The mean participant age was 31 years (range 29 to 34)
in the subgroup of women with submucous fibroids only and 32
years (range 30 to 35) in the subgroup of women with mixed
intramural-submucous fibroids. All women underwent a complete
fertility assessment. Transvaginal ultrasonography was performed
in order to diagnose the presence of uterine fibroids. All women
who were found to be affected by uterine fibroids excluding all
other causes of infertility were asked to participate in the study.
Only women aged ≤ 35 years with a problem of subfertility for
at least one year and the presence of one fibroid of diameter ≤ 40
mm were selected for randomisation. Patients older than 35 years
or with other causes of infertility at the performed examinations
were excluded. Other exclusion criteria were the presence of two or
more fibroids of diameter > 40mm, body weight > 20% of normal
weight; and use of medication containing oestrogens, progestins
or androgens within eight weeks prior to the study.
The second study (Pérez-Medina 2005) included 215womenwith
unexplained,male or female factor infertility for at least 24months
bound to undergo intrauterine insemination with a sonographic
diagnosis of endometrial polyps. There were 101 women in the in-
tervention group and 103 women in the control group; 11 women
were lost to follow-up, six in the intervention group and five in
the control group. The mean participant age was 31 years (range
27 to 35). All women suffered from primary subfertility; they all
underwent a complete fertility assessment. Unexplained infertil-
ity was diagnosed in women with normal ovulatory cycles, semen
analysis, HSG and postcoital testing. Female factor infertility was
diagnosed in women with ovulatory dysfunction, cervical factor
or endometriosis. Male factor infertility was diagnosed if two se-
men analyses obtained at least one month apart were subnormal
according to theWHO criteria. The sonographic diagnosis of en-
dometrial polyps was established by the demonstration of the vas-
cular stalk of the endometrial polyp by colour Doppler in a hyper-
echogenic formation with regular contours occupying the uterine
cavity, surrounded by a small hypoechogenic halo. Women older
than 39 years of age or with anovulation or uncorrected tubal dis-
ease or previous unsuccessful use of recombinant FSH, as well as
women with amale partner with azoospermia, were excluded from
randomisation.
Details of the inclusion and exclusion criteria are found in
Characteristics of included studies.
Interventions
In one trial (Casini 2006) the intervention group was treated with
hysteroscopic surgery to remove the fibroids; transvaginal ultra-
sonography was done three months after the procedure for con-
trol. Women in the intervention group were suggested to abstain
from having sexual intercourse for three months and then to start
having regular fertility-oriented intercourse. Women in the con-
trol group were asked to immediately start having regular fertility-
oriented intercourse. Both groups were monitored for up to 12
months after study commencement.
In the second trial (Pérez-Medina 2005) all hysteroscopic inter-
ventions were done in an outpatient office setting under local
anaesthesia by one gynaecologist. In the intervention group the en-
dometrial polyps suspected on Doppler ultrasound were extracted
by means of a rigid 1.5 mm scissors and forceps through the work-
ing channel of a 5.5 mm continuous flow hysteroscope. All re-
moved polyps were submitted for histopathological examination.
If resection was not possible during the outpatient hysteroscopy,
the woman was scheduled for operative hysteroscopy under spinal
anaesthesia in the operating theatre of the hospital. All the hystero-
scopic interventions were done in the follicular phase of the men-
strual cycle. The women of the intervention group were scheduled
to receive four cycles of IUI, using subcutaneous injections of re-
combinant follicle stimulating hormone (FSH) 50 IU daily from
the third day of the cycle.The first IUI treatment cycle was started
three cycles after the operative hysteroscopy. In the control group
the endometrial polyps suspected on Doppler ultrasound were left
in place during diagnostic hysteroscopy using a 5.5 mm continu-
ous flow hysteroscope; polyp biopsy was performed to establish a
histopathological diagnosis. All women of the control group were
scheduled to receive four cycles of IUI, using subcutaneous injec-
tions of recombinant follicle-stimulating hormone (FSH) 50 IU
daily from the third day of the cycle. The first IUI treatment cycle
was scheduled three cycles after the diagnostic hysteroscopy. Four
IUI cycles were attempted before finishing the trial.
Outcomes
Neither of the two included studies reported data on the primary
outcomes for this review, live birth and hysteroscopy complication
rates.
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The first trial (Casini 2006) measured two secondary outcomes,
clinical pregnancy and miscarriage rate. A clinical pregnancy was
defined by the visualisation of an embryo with cardiac activity at
six to seven weeks of pregnancy. Miscarriage was defined by the
loss of an intrauterine pregnancy between the seventh and 12th
weeks of gestation.
The second trial (Pérez-Medina 2005) reported only one sec-
ondary outcome, the clinical pregnancy rate. This was defined by
a pregnancy diagnosed by ultrasound visualisation of one or more
gestational sacs.
A plausible explanation for the failure to report on the live birth
rate was given by the study authors of one trial (Pérez-Medina
2005). They failed to give an explanation for the lack of data on
the other primary outcome, the hysteroscopy complication rate.
The study authors of the other trial (Casini 2006) could not be
contacted successfully for further clarification on the absence of
reporting the primary outcomes.
Excluded studies
We excluded 20 trials on hysteroscopic interventions for various
reasons.
One trial (Shokeir 2010) was excluded since the main published
report was retracted at the request of the editor of the publish-
ing journal as it duplicates parts of a paper on a different topic
that had already appeared in another journal published years be-
fore (Pérez-Medina 2005). One trial (Pabuccu 2008) is a quasi-
randomised trial. We excluded 18 trials because they did not ad-
dress the pre-specified PICO research questions of this Cochrane
review. Five trials (Aghahosseini 2012; Demirol 2004; El-Nashar
2011; Rama Raju 2006; Shawki 2010) studied the effectiveness
of hysteroscopy in subfertile women bound to undergo IVF or
ICSI treatment with unsuspected or no uterine cavity abnormal-
ities. Three trials (Lieng 2010a; Muzii 2007; van Dongen 2008)
were excluded because the study population included women not
of reproductive age suffering from gynaecological problems other
than subfertility. One trial (Vercellini 1993) was excluded because
the study population included only women with repeated mis-
carriage. Six trials (Acunzo 2003; Amer 2010; De Iaco 2003; Di
Spiezio Sardo 2011; Guida 2004; Tonguc 2008) studied the effec-
tiveness of adjunctive therapies (hyaluronic acid gel, amnion graft,
cyclical hormone replacement therapy alone or intrauterine device
alone or both co-treatments combined) for the prevention of in-
trauterine adhesions following hysteroscopic adhesiolysis. Three
trials (Colacurci 2007; Darwish 2008; Parsanezhad 2006) com-
pared different surgical techniques for treating uterine septum in
a mixed study population of women suffering from subfertility or
recurrent pregnancy loss.
See the table Characteristics of excluded studies.
Studies awaiting classification
Two trials are awaiting classification (Pansky 2009; Trnini -Pjevi
2011). One trial (Pansky 2009) is completed but no published
report could be retrieved from the literature search and we failed
to contact the study authors. A second trial (Trnini -Pjevi 2011)
published in a non-English journal is a clinical controlled trial
with unclear random sequence generation. We failed to contact
the study authors successfully.
See the table Characteristics of studies awaiting classification.
Ongoing studies
Six trials are ongoing (Broekmans 2010; El-Khayat 2012; El-
Toukhy 2009; Maramazi 2012; Revel 2011; Sohrabvand 2012).
See the table Characteristics of ongoing studies.
Risk of bias in included studies
See the ’Risk of bias’ summary for the review authors’ judgements
about each risk of bias item in the included study (Figure 2).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
See the ’Risk of bias’ graph for the review authors’ judgements
about each risk of bias item presented as percentages across the
two included studies (Figure 3).
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We judged both studies included in the Cochrane review (Casini
2006; Pérez-Medina 2005) to be at low risk of selection bias re-
lated to random sequence generation, as both used computerised
random numbers tables.
We judged one study (Pérez-Medina 2005) to be at low risk for se-
lectionbias related to allocation concealment, as sequentially num-
bered, opaque, sealed envelopes were used to conceal the random
allocation of women to one of the comparison groups. We judged
the second trial (Casini 2006) to be at an unclear risk for selection
bias related to allocation concealment since the used method was
not reported and no further clarification by the authors could be
obtained.
Blinding
The risk of bias items ’blinding of participants and personnel’
and ’blinding of outcome assessors’ were not assessed for either of
the included studies as pre-specified and justified in the published
protocol for this review (see Bosteels 2011 and Assessment of risk
of bias in included studies). The editorial reviewers nevertheless
insisted on keeping the two items of blinding activated in the ’Risk
of bias’ tool in the final review while indicating in the ’Risk of
bias’ table of included studies that they were not assessed. Given
that all six items were consequently presented in the ’Risk of bias’
summary and the ’Risk of bias’ graph, we decided to categorise
the two non-assessed items as ’at unclear risk of bias’ rather than
’high risk of bias’ since a lack of blinding will not increase the
risk of bias in studies with a complete follow-up and unequivocal
outcomes. The items were not assessed as ’at low risk of bias’ since
we aimed to avoid upgrading of the quality of evidence based on
items which were not assessed. A sensitivity analysis comparing
the use of ’at low risk of bias’ rather than ’at unclear risk of bias’
did not affect the grading of the quality of the evidence for the
two included studies.
Incomplete outcome data
We judged both studies included in the Cochrane review to
be at low risk of attrition bias. One study (Casini 2006) re-
ported outcome data of all randomised women. The second study
(Pérez-Medina 2005) analysed themajority of women randomised
(95%). The missing outcome data in the remaining 5% were bal-
anced in numbers with similar reasons for missing data between
the two comparison groups.
Selective reporting
We judged both studies included in the review (Casini 2006;
Pérez-Medina 2005) to be at unclear risk of reporting bias. No
protocols were available for further analysis for either trial. All
outcomes reported in the results sections were clearly pre-spec-
ified in the methods sections of the published study reports of
both trials. Both studies (Casini 2006; Pérez-Medina 2005) failed
to include data for the primary outcome live birth, which could
reasonably have been reported in studies conducted over a seven-
year (Casini 2006) and a four-year (Pérez-Medina 2005) pe-
riod. A plausible explanation was given by the contact author of
one study (Pérez-Medina 2005); nevertheless we judged that it
could have been possible to obtain data on the live birth rates if
the study authors had contacted the referring gynaecologists (see
Characteristics of included studies). Moreover no data on adverse
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outcomes such as miscarriage or hysteroscopy complications were
reported in one trial (Pérez-Medina 2005), whereas the second
study reportedmiscarriage rates only for the adverse events (Casini
2006).
Other potential sources of bias
We judged one study to be at unclear risk of other potential sources
of bias (Casini 2006). The mean ages and duration of infertility
in the intervention and control group of women with submucous
fibroids were not reported; we failed to obtain these data from the
study authors given that we were unsuccessful in contacting them.
It is unclear whether there might be imbalance in the baseline
characteristics between the comparison groups in this randomised
trial (Casini 2006). We judged the second study (Pérez-Medina
2005) to be at low risk of other potential sources of bias since there
was no evidence of baseline imbalance in the patient characteristics
between the two comparison groups.
Publication bias could not be formally assessed due to the very
limited number of studies included in this Cochrane review.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
1. Operative hysteroscopy versus control in women
with otherwise unexplained subfertility and suspected
major uterine cavity abnormalities
Endometrial polyps
No studies were retrieved.
Submucous fibroids
We retrieved only one study comparing hysteroscopic myomec-
tomy versus regular fertility-oriented intercourse in women with
unexplained subfertility and submucous fibroids only or combined
with intramural fibroids (Casini 2006).
Primary outcomes
1.1. Live birth
There were no data for this primary outcome.
1.2. Adverse events: hysteroscopy complications
There were no data for this primary outcome.
Secondary outcomes
1.3. Clinical pregnancy
In women with otherwise unexplained subfertility for at least one
year and one submucous fibroid of diameter ≤ 40 mm, there is
no evidence for an effect favouring the removal of the fibroid by
hysteroscopy compared to regular fertility-oriented intercourse for
the secondary outcome of clinical pregnancy. Although hystero-
scopic myomectomy tends to increase the odds of clinical preg-
nancy, the difference between the comparison groups is not statis-
tically significant (odds ratio (OR) 2.4, 95% confidence interval
(CI) 0.97 to 6.2, P = 0.06, one randomised controlled trial (RCT),
94 women) (Analysis 1.1; Figure 4). Considering the minimally
important clinical difference (MICD), we pre-specified in the pro-
tocol (Bosteels 2011) that a MICD of 5% for the live birth rate
would be considered as being relevant for the benefits of the inter-
vention. The data for the one secondary outcome studied indicate
a clinically important difference of 18% (95% CI 0% to 37%, P =
0.05) between the two comparison groups. This is a post hoc anal-
ysis. Although there might be a clinically relevant increase in the
clinical pregnancy rate after hysteroscopic removal of submucous
fibroids in women with otherwise unexplained subfertility com-
pared to expectant management, there is uncertainty concerning
the true point estimate of the clinical effect due to imprecision.
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Figure 4. Forest plot of comparison: 1 Hysteroscopic myomectomy vs regular fertility-oriented intercourse
in women with unexplained subfertility and submucous fibroids.Outcome: 1.1 Clinical pregnancy.
1.4. Adverse events: miscarriage
There is no evidence for an effect of the hysteroscopic removal of
one submucous fibroid of diameter≤ 40 mm in subfertile women
with otherwise unexplained subfertility compared to regular fertil-
ity-oriented intercourse for the secondary outcome of miscarriage
(OR 1.5, 95% CI 0.47 to 5.00, P = 0.47, one RCT, 94 women)
(Analysis 1.2; Figure 5).
Figure 5. Forest plot of comparison: 1 Hysteroscopic myomectomy vs regular fertility-oriented intercourse
in women with unexplained subfertility and submucous fibroids. Outcome: 1.2 Miscarriage.
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Subgroup analyses
No subgroup analyses across studies could be done to assess any
overestimation of treatment effect or reporting bias due to the
limited number of studies.
One pre-specified subgroup analysis within the trial was done for
the two secondary outcomes of clinical pregnancy and miscarriage
according to whether submucous fibroids only or mixed submu-
cous-intramural fibroids were considered. There is no evidence for
an effect favouring the hysteroscopic removal of one submucous
fibroid≤ 40 mm in subfertile women with otherwise unexplained
subfertility compared to regular fertility-oriented intercourse for
the secondary outcome clinical pregnancy in the ’submucous only’
subgroup (OR 2.0, 95% CI 0.62 to 6.7, P = 0.24, one RCT, 52
women) or the ’mixed submucous-intramural’ subgroup (OR 3.2,
95% CI 0.72 to 15, P = 0.13, one RCT, 42 women); the tests
for subgroup differences demonstrated no evidence of statistical
heterogeneity (Chi² = 0.22, df = 1 (P = 0.64), I² = 0%). There
were no differences concerning the hysteroscopic removal of one
submucous fibroid ≤ 40 mm in subfertile women with otherwise
unexplained subfertility compared to regular fertility-oriented in-
tercourse for the secondary outcome miscarriage in the ’submu-
cous only’ subgroup (OR 1.3, 95% CI 0.27 to 6.0, P = 0.77, one
RCT, 52 women) or the ’mixed submucous-intramural’ subgroup
(OR 2.0, 95% CI 0.32 to 12, P = 0.46, one RCT, 42 women);
the tests for subgroup differences demonstrated no evidence of
statistical heterogeneity (Chi² = 0.14, df = 1 (P = 0.71), I² = 0%).
Sensitivity analyses
No sensitivity analyses could be done for live birth due to the lack
of data for this primary outcome. Sensitivity analysis comparing
the use of risk ratio rather than odds ratio as the effect measure did
not affect the statistical significance of themain analysis for the sec-
ondary outcomes ’clinical pregnancy’ (P = 0.07) and ’miscarriage’
(P = 0.47). Sensitivity analysis comparing the inclusion of women
with mixed intramural-submucous fibroids, rather than submu-
cous fibroids only, did not affect the statistical significance of the
main analysis for the secondary outcomes ’clinical pregnancy’ (P
= 0.06) (Analysis 1.1) and ’miscarriage’ (P = 0.47) (Analysis 1.2).
Uterine septum
No studies were retrieved.
Intrauterine adhesions
No studies were retrieved.
2. Operative hysteroscopy versus control in women
undergoing medically assisted reproduction (MAR)
with suspected major uterine cavity abnormalities
Endometrial polyps prior to intrauterine insemination (IUI)
We retrieved only one study comparing hysteroscopic removal of
polyps versus diagnostic hysteroscopy and polyp biopsy in women
with endometrial polyps undergoing gonadotropin treatment and
IUI (Pérez-Medina 2005).
Primary outcomes
2.1. Live birth
There were no data for this primary outcome.
2.2. Adverse events: hysteroscopy complications
There were no data for this primary outcome.
Secondary outcomes
2.3. Clinical pregnancy
The hysteroscopic removal of polyps with a mean size of 16 mm,
detected byDoppler ultrasonography inwomenwith unexplained,
male or female factor infertility for at least 24 months bound to
undergo IUI, increases the odds of clinical pregnancy compared
to diagnostic hysteroscopy and biopsy only (OR 4.4, 95% CI 2.5
to 8.0, P < 0.00001, one RCT, 204 women) (Analysis 2.1; Figure
6). The number needed to treat to benefit is 3 (95% CI 2 to 4).
These results are based on an ’available data’ analysis. The data for
the one secondary outcome studied indicate a clinically important
difference of 35% (95% CI 22% to 48%, P < 0.00001) between
the two comparison groups favouring hysteroscopic polypectomy.
There is evidence of a clinically important increase of the clinical
pregnancy rate favouring hysteroscopic polypectomy compared
to diagnostic hysteroscopy and polyp biopsy. This is a post hoc
analysis, which was not pre-specified by the authors of the primary
study.
20Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 6. Forest plot of comparison: 2 Hysteroscopic removal of polyps vs diagnostic hysteroscopy and
biopsy only prior to IUI. Outcome: 2.1 Clinical pregnancy.
2.4. Adverse events: miscarriage
There were no data for this secondary outcome.
Subgroup analyses
Although no subgroup analyses across studies were done to assess
any overestimation of treatment effect or reporting bias given the
limited number of studies, we did two subgroup analyses within
the included study.
A first pre-specified subgroup analysis studied the effect of
polyp size on the secondary outcome of clinical pregnancy. On
histopathological examination themean size of the polyps removed
was 16 mm (range 3 to 24 mm). In the primary study the effect
of the polyp size on the clinical pregnancy rate was studied in the
intervention group. The data were analysed based on the size of
the removed polyps, subdivided into four groups based in their
quartiles (< 5 mm, 5 to 10 mm, 11 to 20 mm and > 20 mm); the
differences between these four subgroups within this study were
not statistically significant (P = 0.32) (Table 1). There is no ev-
idence of an effect of the polyp size on the outcome of clinical
pregnancy, but these results should be interpreted carefully given
the limited numbers in only one included study. There were no
data on the estimated size of the polyps in the control group.
The second subgroup analysis studied the effect of the timingof the
IUI treatment after hysteroscopy on the secondary outcome clin-
ical pregnancy. About 29% of women in the polypectomy group,
compared to 3% in the diagnostic hysteroscopy group became
pregnant in the three-month period after the hysteroscopy before
the treatment with gonadotropin and IUI was started; this was cal-
culated from the Kaplan-Meier survival analysis in the published
report of the primary study (Pérez-Medina 2005). Hysteroscopic
polypectomy increases the odds of clinical pregnancy compared
to diagnostic hysteroscopy and polyp biopsy in women waiting to
be treated with gonadotropin and IUI (OR 13, 95% CI 3.9 to 46,
P < 0.0001, one study, 204 women, available data analysis). The
number needed to treat to benefit after hysteroscopic polypectomy
while waiting for further treatment with gonadotropin and IUI is
4 (95% CI 3 to 6). In women who started gonadotropin and IUI
treatment the pregnancy rates per woman were 49% and 26% in
the intervention and control group respectively, calculated from
data in the published report of the primary study (Pérez-Medina
2005). Hysteroscopic polypectomy increases the odds of clinical
pregnancy in women who started from three months after the sur-
gical procedure with gonadotropin and IUI treatment (OR 2.7,
95% CI 1.4 to 5.1, P = 0.003, one RCT, 172 women, available
data analysis). The number needed to treat to benefit when treated
with gonadotropin and IUI after a prior hysteroscopic polypec-
tomy is 4 (95% CI 3 to 12). We judged this to be an honest and
sensible post hoc analysis. Quoting from the primary study pub-
lished report “A second important conclusion in our study is that
pregnancies after polypectomy are frequently obtained spontaneously
while waiting for the treatment, suggesting a strong cause-effect of the
polyp in the implantation process. This led us to defer the first IUI
to three menstrual cycles after the polypectomy is performed. Longer
series are needed to verify these results”.
Sensitivity analyses
No sensitivity analyses were done for the outcome of live birth due
to the lack of data for this primary outcome. Sensitivity analysis
comparing the use of risk ratio rather than odds ratio as the effect
measure did not affect the statistical significance of the main anal-
ysis for the secondary outcome ’clinical pregnancy’ (P < 0.00001)
(Analysis 2.1). A sensitivity analysis comparing an intention-to-
treat analysis assuming that clinical pregnancies would not have
occurred in participants with missing data, rather than an ’avail-
able data’ analysis, did not affect the statistical significance of the
main analysis for the secondary outcome ’clinical pregnancy’ (OR
4.0, 95% CI 2.3 to 7.2, P < 0.00001, one RCT, 215 women
randomised). No other imputation strategies for dealing with the
missing data were assumed given the limited number of studies.
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Endometrial polyps prior to in vitro fertilisation (IVF)
No studies were retrieved.
Endometrial polyps prior to intracytoplasmic sperm
injection (ICSI)
No studies were retrieved.
Submucous fibroids prior to IUI
No studies were retrieved.
Submucous fibroids prior to IVF
No studies were retrieved.
Submucous fibroids prior to ICSI
No studies were retrieved.
Uterine septum prior to IUI
No studies were retrieved.
Uterine septum prior to IVF
No studies were retrieved.
Uterine septum prior to ICSI
No studies were retrieved.
Intrauterine adhesions prior to IUI
No studies were retrieved.
Intrauterine adhesions prior to IVF
No studies were retrieved.
Intrauterine adhesions prior to ICSI
No studies were retrieved.
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D I S C U S S I O N
Summary of main results
This systematic review aimed to investigate whether the hystero-
scopic treatment of suspected major uterine cavity abnormalities
made a difference to the main outcomes of live birth or pregnancy
and the adverse events - hysteroscopy complications and miscar-
riage - in subfertile women with otherwise unexplained subfer-
tility or before medically assisted reproduction (intrauterine in-
semination (IUI), in vitro fertilisation (IVF) and intracytoplas-
mic sperm injection (ICSI)). We searched for studies on two ran-
domised comparisons to study the effectiveness of operative hys-
teroscopy in the treatment of subfertility associated with major
uterine cavity abnormalities. The first major randomised com-
parison is operative hysteroscopy versus control in women with
otherwise unexplained subfertility and suspected major uterine
cavity abnormalities - stratified into endometrial polyps, submu-
cous fibroids, intrauterine adhesions or septate uterus - diagnosed
by ultrasonography (US), saline infusion/gel instillation sonog-
raphy (SIS, GIS), hysterosalpingography (HSG), diagnostic hys-
teroscopy or any combination of these methods. The second ran-
domised comparison is operative hysteroscopy versus control in
womenundergoingmedically assisted reproduction (MAR) - strat-
ified into IUI, IVF or ICSI - with suspected major uterine cav-
ity abnormalities - stratified into endometrial polyps, submucous
fibroids, intrauterine adhesions or septate uterus - diagnosed by
US, SIS, GIS, HSG, diagnostic hysteroscopy or any combination
of these methods.
We critically appraised one single trial (Casini 2006) comparing
hysteroscopic removal of one submucous fibroid with a diameter
≤ 40 mm in women aged≤ 35 years with otherwise unexplained
subfertility versus regular fertility-oriented intercourse for a pe-
riod of 12 months. There is no evidence of an effect favouring the
removal of submucous fibroids by hysteroscopy in women with
otherwise unexplained subfertility compared to expectant man-
agement for the secondary outcome of clinical pregnancy. We did
not retrieve any trials on operative hysteroscopy versus control in
women with otherwise unexplained subfertility and suspected en-
dometrial polyps, intrauterine adhesions or septate uterus.
We found only one single trial (Pérez-Medina 2005) for the sec-
ond category of randomised interventions. According to the re-
sults of the randomised comparison ’hysteroscopic polypectomy
versus diagnostic hysteroscopy comparison in subfertile women
with suspected endometrial polyps bound to undergo IUI’, there
is evidence for a clinically relevant and statistically significant in-
crease in the odds of clinical pregnancy favouring the hystero-
scopic removal of polyps with a mean size of 16 mm (range 3 to
24 mm). There were no data for the primary outcomes of live
birth and hysteroscopy complications and the secondary outcome
of miscarriage. The increase in clinical pregnancies after hystero-
scopic polypectomy might be mainly due to a higher proportion
of spontaneous conceptions before starting IUI and to a lesser, but
still clinically relevant, extent to a higher odds of conceiving after
starting gonadotropin treatment and IUI. The results of this sen-
sible post hoc subgroup analysis should be interpreted with cau-
tion; at present no definitive conclusions can be made concerning
the timing of the hysteroscopic intervention in relationship to the
subsequent IUI treatment. There is no evidence for an effect of
the size of the polyps on the outcome clinical pregnancy, but given
the limited numbers this subgroup analysis should equally be in-
terpreted with caution. No data on the polyp size were available
from the control group: given the arbitrary distinction between
biopsying or removing a very small polyp, the probability that the
true treatment effect of hysteroscopic polypectomy might even
have been underestimated can neither be proven nor ruled out.
Overall completeness and applicability of
evidence
Evidence on the effectiveness of treating suspected major uterine
cavity abnormalities by operative hysteroscopy compared to a con-
trol intervention in women with otherwise unexplained subfertil-
ity is very limited. We found no trials on the hysteroscopic treat-
ment of endometrial polyps, intrauterine adhesions or septa com-
pared to a control intervention in women with otherwise unex-
plained subfertility. The only included study in this category fails
to report on the primary outcomes for this review. Evidence on
the effectiveness of operative hysteroscopy compared to control in
subfertile women with associated major uterine cavity abnormal-
ities prior to medically assisted reproduction is incomplete since
data have been found only for subfertile women with suspected
endometrial polyps prior to IUI. No data were retrieved on the
effectiveness of operative hysteroscopy versus control in subfertile
women with other suspected major cavity abnormalities such as
submucous fibroids, intrauterine adhesions or septa prior to IUI or
other techniques such as IVF or ICSI for all outcomes. Moreover
for the randomised comparison hysteroscopic polypectomy ver-
sus diagnostic hysteroscopy prior to IUI no data are available for
the primary outcomes. The evidence retrieved is by consequence
insufficient to address all the objectives of the present Cochrane
review.
The lack of statistical significance of the differences between the
comparison groups in the trial of hysteroscopic myomectomy in
women with submucous fibroids and otherwise unexplained sub-
fertility does not exclude the possibility of a clinically relevant
benefit favouring hysteroscopic surgery. It is generally accepted
that submucous fibroids are very likely to interfere with normal
fertility (Pritts 2001; Pritts 2009). In everyday practice the ma-
jority of skilled hysteroscopists will counsel women with submu-
cous fibroids associated with otherwise unexplained subfertility or
bound to be treated with IUI, IVF or ICSI to have the submucous
fibroids removed before further expectant management or MAR.
Although the results of the trial on hysteroscopic polypectomy
(Pérez-Medina 2005) are relevant for everyday practice, one-third
of the randomised women treated by IUI suffered from ovulatory
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disorder. In everyday clinical practice ovulatory disorder is by itself
not an indication for IUI as opposed to male factor (Bensdorp
2007) and unexplained subfertility (Veltman-Verhulst 2012). We
have considered doing a sensitivity analysis to study if the inclu-
sion and exclusion of women with ovulatory disorders could have
influenced the magnitude of the treatment effect but failed to ob-
tain the data from the study authors.
Quality of the evidence
See Table 2 and Table 3. See also Summary of findings for the
main comparison and Summary of findings 2.
The present review included only two trials; neither reported the
primary outcomes live birth or hysteroscopy complications.
Using the GRADE tool as implemented in GRADE profiler, we
graded the evidence of the first trial onhysteroscopicmyomectomy
(Casini 2006) as ’very low’. It is a small study with few events. The
key methodological limitations of this study are twofold: there is
uncertainty about allocation concealment and it is unclearwhether
there was imbalance in the baseline characteristics of the study
groups. Moreover, the results are imprecise given the wide confi-
dence intervals of the point estimate of the treatment effect. The
effect of imprecision is to make the observed association closer
to the null value than is the true association. The pre-planned
subgroup analysis in terms of removal of submucous fibroids only
or mixed-submucous intramural fibroids showed no evidence for
an effect favouring the removal of fibroids compared to regular
fertility-oriented intercourse; the absence of a treatment effect is
consistent with the findings for the removal of submucous fibroids
’overall’. Although the interpretation of the statistical analysis of
subgroups is problematic, there is no evidence of serious inconsis-
tency.
The evidence of the second trial on hysteroscopic polypectomy
(Pérez-Medina 2005) was graded as ’high’: despite some poten-
tial for reporting bias (see Assessment of risk of bias in included
studies) we upgraded the quality of the evidence of this study given
the strong association provided by the magnitude of the treatment
effect (risk ratio (RR) > 2; see the Cochrane Handbook for System-
atic Reviews of Interventions version 5.1.0 - section 12.2.3, Higgins
2011). This study had adequate statistical power to detect a differ-
ence between the comparison groups. There was no evidence for a
dose-response relationship between the size of the polyps and the
treatment effect of the hysteroscopic polypectomy according to the
only pre-specified subgroup analysis. These findings should nev-
ertheless be interpreted with great caution. According to a sensible
post hoc analysis the treatment effect of hysteroscopic polypec-
tomy is consistent among the subgroups of women waiting to be
treated after hysteroscopy with gonadotropins and IUI and those
who started gonadotropin treatment and IUI. Nevertheless, the
use of post hoc analyses looking at subgroups after the trial has
been conducted is open to potential problems of multiple com-
parisons and comparisons between non-randomised groups.
Potential biases in the review process
There is an earlier published version of this review (Bosteels 2010).
Given our prior knowledge of potentially eligible studies for this
clinical research topic, there might have been some potential for
detection bias. We aimed to carry out a comprehensive literature
search using a search strategy which was more extensive than the
one used in the earlier published systematic review. This enabled
us to identify a far greater number of randomised studies on hys-
teroscopic surgery in subfertile women, many of which do not
address the particular research questions pre-specified in the pro-
tocol (see Characteristics of excluded studies).
Agreements and disagreements with other
studies or reviews
There are two systematic reviews on fibroids and subfertility (Pritts
2001; Pritts 2009). We refer to the data in the most recent review
since theMOOSE (Meta-analysis of Observational Studies in Epi-
demiology) guidelines for systematic reviews of observational stud-
ies were followed (Pritts 2009). Two types of observational studies
were identified: those controlling with women having fibroids in
situ, and those using subfertile women without fibroids as con-
trol participants. If fibroid removal is beneficial, women treated by
myomectomy would be expected to have higher pregnancy rates
and lower miscarriage rates than those with fibroids in situ. In
women with submucous fibroids, the clinical pregnancy rates were
higher in the myomectomy group (RR 2.0, 95% CI 1.1 to 3.8,
two studies, P = 0.028). The differences between both groups for
the ongoing pregnancy/live birth rates failed to reach statistical
significance (RR 2.6, 95% CI 0.92 to 7.6, one study, P > 0.05).
There was no evidence for differences in the miscarriage rates be-
tween both groups (RR 0.77, 95% CI 0.36 to 1.7, one study,
P > 0.05). When the control group consists of subfertile women
without fibroids, myomectomy might be expected (if beneficial)
to normalise the rates compared with controls. For women with
submucous fibroids treated by hysteroscopic myomectomy, there
was no evidence for statistically significant differences in clinical
pregnancy rates (RR 1.5, 95% CI 1.0 to 2.4, two studies, P >
0.05), ongoing pregnancy/live birth rates (RR 1.1, 95% CI 1.0 to
1.3, three studies, P > 0.05) andmiscarriage rates (RR 1.2, 95%CI
0.47 to 3.2, two studies, P > 0.05) compared to subfertile women
without submucous fibroids. Meta-regression demonstrated that
the study quality scores did not significantly affect the observed
effect in the meta-analyses. Furthermore, sensitivity analyses com-
paring the use of the studies with the highest study quality did not
affect the statistical significance of the main results compared to
the use of all the retrieved studies, irrespective of the study qual-
ity. There was no evidence of publication bias in the systematic
review of the literature done by this research group. The authors
concluded that the fertility outcomes are decreased in women with
submucosal fibroids, and removal is likely to benefit the reproduc-
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tive outcome.
The results of the trial on the effectiveness of hysteroscopic
polypectomy prior to IUI are consistent with the findings of two
recently published observational studies. The first study planned
to evaluate the effect of the presence of endometrial polyps onpreg-
nancy rates and how polypectomy could affect pregnancy rates in
171 women scheduled for IUI (Kalampokas 2012). The presence
of an endometrial polypwas diagnosed during the infertility evalu-
ation. The study group consisted of 86 women who, following the
diagnosis of endometrial polyp, agreed to have the polyps removed
hysteroscopically prior to the IUI. The control group consisted of
85 women who, despite the fact that the presence of an endome-
trial polyp was previously diagnosed and its removal suggested,
elected not to have the polyp removed. There was a statistically sig-
nificant difference in cumulative pregnancy rates between the two
groups, favouring hysteroscopic polypectomy. The authors con-
cluded that hysteroscopic polypectomy appears to improve fertil-
ity in women with otherwise unexplained infertility. The second
study, a prospective clinical controlled study including120women
with endometrial polyps, aimed to study whether polypectomy
before intrauterine insemination achieved better pregnancy out-
comes than no intervention (Shohayeb 2011). All patients were
scheduled to receive four cycles of IUI in both groups within 12
months duration. The first IUI cycle was planned after three men-
strual cycles in both groups. Cumulative pregnancy rate in both
groups after four IUI cycles was 23 (38.3%) in the study group
and 11 (18.3%) in the control group (P = 0.015). The authors
concluded that persistent endometrial polyps are likely to impair
reproductive performance and that hysteroscopic polypectomy be-
fore IUI could be considered as an effective intervention. A sys-
tematic review (Lieng 2010b) included 11 studies in 935 subfer-
tile women with endometrial polyps: one randomised controlled
trial (Pérez-Medina 2005), three clinical controlled studies and
seven observational studies (three retrospective, one prospective
and three undetermined). Although there was no evidence for an
effect favouring hysteroscopic polypectomy on the IVF outcomes
according to two smaller non-randomised observational studies,
the limited evidence suggests a favourable outcome on pregnancy
rates in subfertile women with endometrial polyps. Due to the
clinical diversity formal meta-analysis was rightfully judged to
be inappropriate. The methodology for meta-analysis of observa-
tional studies proposed by The Cochrane Collaboration was not
followed (no formal appraisal of the risk of bias, no study of the
effect of confounders, no formal assessment of publication bias);
therefore, the authors’ conclusion should be interpreted with great
caution.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There might be a clinically relevant increase in the odds of con-
ceiving by removing submucous fibroids in women with otherwise
unexplained subfertility compared to expectantmanagement. The
differences in clinical pregnancy rates between both comparison
groups in the single published randomised trial were not statis-
tically significant due to limited numbers; the level of evidence
provided by this single small study was graded as very low.
Before treating subfertile women with a sonographic diagnosis of
endometrial polyps with gonadotropins combined with intrauter-
ine insemination for unexplained, male or female factor infertil-
ity for at least 24 months, it may be advisable to perform a hys-
teroscopic polypectomy to improve the chance of conceiving. The
level of evidence provided by this single study was graded as high.
Implications for research
The evidence retrieved from the limited number of randomised
studies is insufficient to address all the objectives of the present
review.
More well-designed randomised controlled trials are needed to
assess whether the hysteroscopic removal of endometrial polyps,
submucous fibroids, septa or intrauterine adhesions is likely to
benefit women with otherwise unexplained subfertility associated
with these suspected uterine pathologies compared to a control in-
tervention. Equally, more clinical research is needed on the effec-
tiveness of treating endometrial polyps, submucous fibroids, septa
or intrauterine adhesions in subfertile women bound to undergo
IUI, IVF or ICSI.
There are knowledge gaps concerning the effects of the number,
size or extent and the localisation of the major uterine cavity ab-
normalities on the main outcomes in women with otherwise un-
explained subfertility or prior to medically assisted reproduction.
Well-designed randomised studies are needed to assess the rela-
tionship between the timing of the hysteroscopic intervention and
subsequent IUI, IVF or ICSI treatment.
Future randomised studies should report on primary outcomes
such as live birth and adverse events such as miscarriage and hys-
teroscopic complications.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Casini 2006
Methods Parallel-group, randomised, controlled, single-centre trial
Power calculation not reported
Approved by the hospital’s ethics committee
No source of funding or conflict of interest reported
Participants Country: Italy
Setting: AGUNCO Obstetrics and Gynecology Centre, Rome
Population: women referred to the centre from January 1998 until April 2005 for fertility
problems were examined for inclusion in the study. All women underwent routine exam-
inations including the study of ovarian function (follicle-stimulating hormone, lutein-
ising hormone, estradiol and progesterone concentrations); prolactin, free triiodothyro-
nine, free thyroxine and thyroid-stimulating hormone concentrations; post-coital test;
transvaginal ultrasonography; hysterosalpingography; and analysis of the partner’s se-
men. The transvaginal ultrasonography was performed in order to diagnose the presence
of uterine fibroids. After these examinations all patients who were found to be affected
by uterine fibroids excluding all other causes of infertility were asked to participate in
the study
Type of subfertility: all women had been suffering from infertility for at least 1 year
(range: 1 to 5 years); no further clarification on primary versus secondary subfertility
Mean age: the mean age in the patients with submucous fibroids alone was 31.4 ± 2.5
years; the mean age in the patients with mixed submucous-intramural fibroids was 32.2
± 2.5 years
N recruited = 193 women
N participants = 181 women
N participants with submucous fibroids only = 52 women
N participants with mixed submucous-intramural fibroids = 42 women
Inclusion criteria: age ≤ 35 years; infertility for at least 1 year; presence of one knot
and/or fibroid of diameter ≤ 40 mm and absence of other causes of infertility at the
performed examinations
Exclusion criteria: presence of 2 or more knots and/or fibroids of diameter > 40 mm;
body weight > 20% of normal weight; and use of medication containing oestrogens,
progestins or androgens within 8 weeks prior to the study
Duration of the study: 86 months; the study was conducted from January 1998 until
April 2005
Interventions 2 interventions were compared:
• The intervention group was treated with hysteroscopic surgery to remove the
fibroids (n = 52)
• The control group was not treated (n = 42)
Patients were examined by transvaginal ultrasonography 3 months after surgery for con-
trol
Patients who did not undergo surgery were asked to immediately start having regular
fertility-oriented intercourse (intercourse during the 6-day fertile interval ending on
the day of ovulation). Patients who underwent surgery were suggested to abstain from
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Casini 2006 (Continued)
having sexual intercourse for 3 months and then to start having regular fertility-oriented
intercourse
Patients were monitored for up to 12 months after study commencement
Outcomes A clinical pregnancy was defined by the visualisation of an embryo with cardiac activity
at 6 to 7 weeks of pregnancy
Miscarriage was classified as clinical loss of an intrauterine pregnancy between the 7th
and 12th weeks of gestation
Notes The authors state that the differences in pregnancy rates between the comparison groups
are statistically significant for the patients with submucous fibroids (P < 0.05), which is
in contrast with the calculation of the results in RevMan
The definition of knot is unclear: it could not be clarified since we failed to contact the
study authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subsequently, women of each group
were randomized into two subgroups, accord-
ing to a randomization table”
Comment: low risk of selection bias related
to random sequence generation
Allocation concealment (selection bias) Unclear risk Method not stated: no further clarification
obtained from the study authors
Comment: unclear risk of selection bias re-
lated to allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This item was not assessed as justified in
the protocol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This item was not assessed as justified in
the protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One hundred and ninety-three pa-
tients were diagnosed as affected by uterine
fibroid excluding all other causes of infertil-
ity and met the requirements of the inclusion
and exclusion criteria. Of these, 181 decided
to participate in the study. Among the 181
patients, 52 had submucosal fibroids (SM
group) while 45 had intramural fibroids (IM
group), 11 had subserosal fibroids (SS group),
42 had amix of submucosal-intramural (SM-
IM group) and 31 patients had a mix of in-
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Casini 2006 (Continued)
tramural-subserosal fibroids (IM-SS group)”.
Quote: “Out of 181women, 68 become preg-
nant”
Comment: low risk for attrition bias
Selective reporting (reporting bias) Unclear risk Quote from the abstract: “The main out-
come measures were the pregnancy rate and
the miscarriage rate”.
Quote from the results’ section: “Out of 181
women, 68 become pregnant. Pregnancy rates
according to the location of the fibroids and
the different treatments are reported in Table
II. Among the 68 women who became preg-
nant, 25 had a miscarriage”.
Comment: unclear risk for reporting bias.
Although the main outcomes specified in
the abstract were measured and reported
in the results section, no study protocol
could be obtained. The published report
fails to include results for the live birth rate,
which is the primary outcome of interest
that would be expected to have been re-
ported for a trial on fertility treatment con-
ducted over a 7-year period
Other bias Unclear risk The mean ages and duration of infertility
in the intervention and control group of
womenwith submucous fibroids are not re-
ported. No further clarification by the au-
thors was obtained
It is unclear whether there might have been
imbalance in the baseline characteristics be-
tween the comparison groups
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Pérez-Medina 2005
Methods Parallel-group, randomised, controlled, single-centre trial
A power analysis was performed. To detect an expected difference in pregnancy rate
between the intervention and control group of 15% at a level of 0.05 with a power of
80%, a sample size of 200 women (i.e. 100 women per group) was required. From 2800
women attending the centre, 452 women fulfilling the inclusion criteria were selected;
215 women were randomised (107 women in the intervention group and 108 women in
the control group). Data on outcomes of 204 women were available for analysis (101 in
the intervention group and 103 in the control group). This study had therefore adequate
statistical power to detect a difference between the comparison groups if really present
Approved by the hospital’s ethics committee
No source of funding or conflict of interest reported
Participants Country: Spain
Setting: infertility unit of an university tertiary hospital in the Spanish capital Madrid
Population: women with unexplained, male or female factor infertility for at least 24
months bound to undergo intrauterine insemination with a sonographic diagnosis of
endometrial polyps
Unexplained infertility was diagnosed in patients with normal ovulatory cycles, semen
analysis, HSG and postcoital testing. Male factor infertility was diagnosed if 2 semen
analyses obtained at least 1 month apart were subnormal according to theWHO criteria.
Female factor infertility was diagnosed in patients with ovulatory dysfunction, cervical
factor or endometriosis
Type of subfertility: primary subfertility (correspondence with the study authors)
Mean age: treatment group = 30.8 years (26.7 to 34.9), control group = 30.9 years (26.
5 to 35.3)
N recruited = 452 women
N randomised = 215 women
Inclusion criteria: women with at least 24 months of subfertility with a sonographic
diagnosis of endometrial polyps bound to undergo intrauterine insemination for unex-
plained, male or female factor infertility
Exclusion criteria: women > 39 years of age, anovulation, azoospermia, uncorrected tubal
disease or previous unsuccessful use of recombinant FSH
Duration of the study: 50 months; the study was conducted from January 2000 to
February 2004
Interventions One surgeon (the first author of the study TP-M) performed all hysteroscopic procedures
by intention in an outpatient office setting under local anaesthesia
2 interventions were compared:
• Hysteroscopic polypectomy using a 5.5 mm continuous flow office hysteroscope
with a 1.5 mm scissors and forceps (n = 107)
• Diagnostic hysteroscopy using a 5.5 mm continuous flow office hysteroscope and
polyp biopsy (n = 108)
Duration: women were scheduled to receive 4 cycles of IUI with subcutaneous injection
of recombinant FSH 50 IU daily from the third day, and the first IUI was planned for
3 cycles after hysteroscopy in both groups. 4 IUI cycles were attempted before finishing
the trial
Outcomes Primary: Quote: “We studied the crude pregnancy rate in both groups”
Comment: clinical pregnancy; crude pregnancy was defined by the study authors as
follows: “the presence of a gestational sac on ultrasound” (correspondence with the study
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authors)
Secondary: time-to-pregnancy and influence of the size of the endometrial polyps on the
pregnancy rate
Notes 1. Quote: “Patients underwent a complete infertility evaluation that included TVUS in the
early proliferative phase, basal body temperature recording to assess ovulation, postcoital test
(PCT), HSG, semen analysis and, in some patients, diagnostic laparoscopy”
Comment: according to correspondence with the first author, the aim of the laparoscopy
was exclusively diagnostic in the evaluation of cases of unexplained infertility of un-
known origin. If tubal pathology was detected by laparoscopy, the patient was excluded
from randomisation. The numbers of women undergoing a laparoscopy were balanced
between the 2 comparison groups
2. In this study IUI was performed for various indications: male factor (21%), cervical
factor (11%), endometriosis (11%), or unexplained subfertility (49%) and ovulation
disorder (33%). Anovulation is reported in themethods section as an exclusion criterion.
The study authors defined ovulation disorder as follows: Quote: “A combination of irreg-
ular menstrual cycles with multicystic ovaries on TVUS and basal gonadotrophin measure-
ments within the normal range” (correspondence with the first study author). Comment:
In everyday clinical practice ovulation disorder is not an indication for IUI by itself
3. Data on the number or the localisation of the polyps could not be retrieved since the
first author no longer works in the university hospital
4. Data on the size of the polyps in the control group could not be obtained for similar
reasons as 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised to one of
the two groups with use of an opaque envelope
technique, with assignment determined by a
computerized random number table”
Quote: “Subjects were randomised into one
of two groups in a 1:1 ratio using a restricted
randomisation”
Comment: probably done, but using sim-
ple randomisation, with an equal alloca-
tion ratio, by referring to a table of random
numbers generated by a computer
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised to one of
the two groups with use of an opaque envelope
technique, with assignment determined by a
computerized random number table”.
Comment: sequentially
numbered, opaque, sealed envelopes were
used according to correspondence with the
first author; probably done
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk This item was not assessed as justified in
the protocol
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk This item was not assessed as justified in
the protocol
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “11 patients were lost from the study,
6 in the study group (3 lost to follow-up, 2
pathologic reports of submucosal myoma and
1 in whom the polyp was not confirmed) and
5 in the control group (1 lost to follow-up, 2
in whom the polyp was not confirmed and 2
pathologic reports of myoma)”
Comment: no intention-to-treat analysis;
missing outcome data are balanced in num-
bers across the comparison groups, with
similar reasons for missing data across
groups
Selective reporting (reporting bias) Unclear risk Quote: “Clinical pregnancy was the main
outcomemeasure analysed to determine the ef-
fectiveness of treatment. We studied the crude
pregnancy rate in both groups. The secondary
outcomes were to compare the time for success
in each group and to determine whether the
size of the endometrial polyp influenced the
pregnancy rate”.
Comment: the study protocol is no longer
available to the first study author since he
no longer works in the tertiary university
fertility centre and has moved to 4 different
hospitals during the last 10 years. Although
the published report includes results on all
the outcomes specified in the methods sec-
tion, it nevertheless fails to include results
for the live birth rate, which is the primary
outcome of interest that would be expected
to have been reported for a trial on fertil-
ity treatment conducted over a 4-year pe-
riod. Data on the outcomes live birth and
miscarriage were not available since most
the majority of randomised women were
referred by gynaecologists from outside the
tertiary university hospital and were re-
ferred back when pregnant for further fol-
low-up by the referring gynaecologist. No
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Pérez-Medina 2005 (Continued)
clarification could be obtained for the lack
of data on hysteroscopic complications
Other bias Low risk No evidence for imbalance in the baseline
characteristics
FSH: follicle-stimulating hormone
HSG: hysterosalpingography
IU: international units
IUI: intrauterine insemination
TVUS: transvaginal ultrasound
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acunzo 2003 Not addressing the research questions described in the protocol
Parallel-group randomised trial studying the efficacy of hyaluronic acid gel in preventing the development of
intrauterine adhesions following hysteroscopic adhesiolysis. Mixed population of women with intrauterine
adhesions, presenting with subfertility or other gynaecological complaints. Primary outcome: adhesion
scores
Aghahosseini 2012 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing hysteroscopy prior to a subsequent IVF attempt versus immediate
IVF without prior hysteroscopy conducted in patients with 2 or more failed IVF cycles with unsuspected
or no uterine cavity abnormalities. Main outcomes: biochemical pregnancy, clinical pregnancy and delivery
rates
Amer 2010 Not addressing the research questions described in the protocol
Parallel-group randomised trial in subfertile women comparing the application of amnion graft, either
fresh or dried to an intrauterine balloon versus the application of an intrauterine balloon without amnion
graft as an adjunctive procedure after the hysteroscopic lysis of severe intrauterine adhesions, diagnosed at
office hysteroscopy in women with infertility with or without menstrual disorders as the primary symptom.
Outcomes assessed were improvement in adhesion grade, improvement in menstruation, increased uterine
length at sounding, complications and reproductive outcome
Colacurci 2007 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing 2 different surgical techniques for metroplasty: operative hys-
teroscopy using the resectoscope with a unipolar knife versus the Versapoint device. Mixed population of
women with septate uterus and a history of recurrent miscarriage or primary subfertility. Outcomes assessed
were operative parameters, complications, need for a second intervention and reproductive outcome pa-
rameters
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Darwish 2008 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing extended sectioning by resectoscopy versus sequential cold knife
excision for treating a complete uterocervicovaginal septum in a mixed population of women suffering from
infertility or pregnancy loss.Main outcomemeasures: operating time, perioperative bleeding, complications,
reproductive outcome, and patient and husband satisfaction
De Iaco 2003 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the application of hyaluronan derivative gel (Hyalobarrier®
gel) after hysteroscopic surgery versus surgical treatment alone in women aged 18 to 65 years, suffering
from other gynaecological conditions than subfertility. Primary outcome: adhesion score at second look
hysteroscopy
Demirol 2004 Not addressing the research questions described in the protocol
Parallel-group randomised comparison between office hysteroscopy prior to a subsequent IVF attempt or
immediate IVF without prior office hysteroscopy conducted in patients with 2 or more failed IVF cycles
with unsuspected or no uterine cavity abnormalities. Outcome measures: number of oocytes retrieved,
fertilisation rate, number of embryos transferred, first trimester miscarriage and clinical pregnancy rates
Di Spiezio Sardo 2011 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the use of Intercoat® absorbable adhesion barrier gel versus no
adhesion barrier after hysteroscopic synechiolysis in a mixed population of women suffering from infertility
or other gynaecological conditions. Primary outcome: incidence of de novo intrauterine adhesions, adhesion
scores, patency of the internal uterine ostium
El-Nashar 2011 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing diagnostic hysteroscopy with directed biopsy and/or hystero-
scopic treatment of unsuspected uterine cavity abnormalities versus no hysteroscopy in women with primary
infertility treated with ICSI. Primary outcome: clinical pregnancy
Guida 2004 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing hysteroscopic surgery for the removal of polyps, fibroids or septa
followed by the application of auto-cross linked hyaluronic acid gel versus hysteroscopic surgery without
the adhesion barrier in a mixed population of women with subfertility and other gynaecological symptoms
associated with endometrial polyps, submucous fibroids or septa. Main outcomes: rates of adhesion forma-
tion and adhesion scores
Lieng 2010a Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing transcervical resection by hysteroscopy of endometrial polyps
suspected onTVUS and SIS versus observation for 6months. The study population included premenopausal
women with bleeding problems associated with endometrial polyps. The aim of the trial was to study the
clinical effectiveness of transcervical resection of endometrial polyps for the outcome periodic blood loss.
Women wishing to become pregnant were excluded from the trial. Primary outcome: periodic blood loss
measured by the Pictorial Blood Assessment Chart
Muzii 2007 Not addressing the research questions described in the protocol
Parallel-group randomised trial in women aged 18 to 75 years comparing operative hysteroscopy using the
monopolar resectoscope versus hysteroscopic bipolar electrode excision for the treatment of endometrial
polyps. Outcomes: operating times, difficulty of the operation, surgeon satisfaction with the procedure,
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complications, postoperative pain and patient satisfaction
Pabuccu 2008 Quasi-randomised trial comparing early second look office hysteroscopic adhesiolysis after hysteroscopic
adhesiolysis and IUD insertion versus no early second look operative hysteroscopy in subfertile women with
intrauterine adhesions. The method of sequence generation is based on alternation: women were allocated
to the intervention or control groups based on their study entry
Main outcomes: pregnancy and live birth rate.
Parsanezhad 2006 Not addressing the research questions described in the protocol
Parallel-group randomised trial in a mixed study population of women with a history of pregnancy wastage
or infertility and an associated complete uterine septum comparing metroplasty with complete section of the
cervical septum versus metroplasty with preservation of the cervical septum. Outcome measures: operating
time, distending media deficit, total distending media used, intraoperative bleeding, complications and
reproductive outcome
Rama Raju 2006 Not addressing the research questions described in the protocol
Parallel-group randomised trial conducted in patients with 2 or more failed IVF cycles with unsuspected
or no uterine cavity abnormalities comparing office hysteroscopy prior to a subsequent IVF attempt or
immediate IVF without prior hysteroscopy. Outcomes: number of oocytes retrieved, fertilisation rate,
number of embryos transferred and clinical pregnancy rates
Shawki 2010 Not addressing the research questions described in the protocol
Parallel-group randomised trial conducted to determine the incidence of unsuspected uterine cavity abnor-
malities detected by office hysteroscopy in patients before ICSI treatment compared to ICSI without prior
hysteroscopy. Main outcomes were the incidence of unsuspected uterine abnormalities and implantation
and clinical pregnancy rates
Shokeir 2010 Published report describing a parallel-group randomised trial comparing hysteroscopic myomectomy versus
diagnostic hysteroscopy andbiopsy inwomenwith otherwise unexplainedprimary infertility and submucous
fibroids. Primary outcome: clinical pregnancy rates
Quote from Fertility and Sterility searched on 16 January 2012: “This article has been retracted at the request
of the editor as it duplicates parts of a paper that had already appeared in Hum. Reprod., 20 (2005) 1632-1635,
DOI:10.1093/humrep/deh822”.
Tonguc 2008 Not addressing the research questions described in the protocol
Parallel-group randomised comparing hysteroscopic lysis of intrauterine adhesions with or without adjunc-
tive therapy (cyclical hormone replacement therapy alone or intrauterine device alone or both co-treatments
combined) after hysteroscopic metroplasty in a mixed population of women with subfertility and/or recur-
rent miscarriage. Main outcomes: incidence of de novo adhesion formation and ongoing pregnancy rate
van Dongen 2008 Not addressing the research questions described in the protocol
Parallel-group randomised trial comparing the hysteroscopic removal of polyps or fibroids by conventional
hysteroscopy using a resectoscope versus hysteroscopic morcellation in a mixed population of women
suffering from infertility or other gynaecological conditions. Outcomemeasures: mean number of insertions
into the uterine cavity and mean operating time
Vercellini 1993 Not addressing the research questions described in the protocol
Parallel-group randomised comparing metroplasty using the resectoscope versus micro scissors for treating
uterine septum in women with repeated miscarriage. Outcome measures: mean operating time, mean
42Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
amount of distension medium used and complications
ICSI: intracytoplasmic sperm injection
IUD: intrauterine device
IVF: in vitro fertilisation
SIS: saline infusion sonography
TVUS: transvaginal ultrasound
Characteristics of studies awaiting assessment [ordered by study ID]
Pansky 2009
Methods Single-centre, prospective, single-blind randomised controlled pilot study
Participants 30 women aged 18 to 50 years with retained products of conception
Interventions Application of Oxiplex/AP gel after hysteroscopic treatment versus no gel after hysteroscopic treatment
Outcomes Primary: safety of intrauterine application of Oxiplex/AP gel defined by immediate and late adverse effects at 18
months such as fever, intrauterine adhesion formation and changes in menstrual pattern
Secondary: efficacy of intrauterine application of Oxiplex/AP gel in reducing adhesion formation following hystero-
scopic treatment for retained products of conception
Notes Current status on 1 November 2012: study completed; we contacted the first author - no response at present
Trnini -Pjevi 2011
Methods Clinical controlled trial - not clear whether random sequence generation was used
Participants This study included 480 women under 38, who had undergone IVF or IVF/ICSI - embryo transfer cycles, in which
one or more good quality embryos were transferred
Interventions Hysteroscopy versus no hysteroscopy
Outcomes Clinical pregnancy
Notes Current status on 1 November 2012: no further clarification by the first author at present
ICSI: intracytoplasmic sperm injection
IVF: in vitro fertilisation
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Characteristics of ongoing studies [ordered by study ID]
Broekmans 2010
Trial name or title SIGnificance ofRoutineHysteroscopyPrior to a First ’inVitro Fertilization’ (IVF)TreatmentCycle - inSIGHT
ClinicalTrials.gov NCT01242852
Methods Multicentre, single-blind, parallel-group randomised controlled trial
Participants Women with primary or secondary infertility due to undergo IVF treatment with normal transvaginal ultra-
sound in the follicular phase of the menstrual cycle
Interventions Office hysteroscopy combined with a saline infusion sonography prior to a first IVF cycle compared to starting
IVF without prior hysteroscopy
Outcomes Primary: ongoing pregnancy
Secondary: costs, implantation rate, miscarriage rate and patient tolerance
Starting date Current status on 1 November 2012: recruiting
Contact information F.J. Broekmans, M.D., PhD
University Medical Center Utrecht, Utrecht the Netherlands 3584CX
Telephone: +31 887551041
e-mail: F.J.Broekmans@Umcutrecht.nl
Notes
El-Khayat 2012
Trial name or title Does office hysteroscopy and endometrial snip improve IUI outcome?: a randomized controlled trial
Methods Allocation: randomised; endpoint classification: efficacy study; interventionmodel: parallel assignment;mask-
ing: single-blind (participant); primary purpose: treatment
Participants Inclusion criteria: 18 to 38 years old, at least 1 patent tube, unexplained infertility or anovulation or mild to
moderate male factor infertility, previous failed IUI
Exclusion criteria: indication for ICSI
Interventions Control group: office hysteroscopy
Intervention group: office hysteroscopy and endometrial snip
Outcomes Primary outcome: clinical pregnancy rate at 10 months
Secondary outcome: ongoing pregnancy rate at 12 months
Starting date Current status on 1 November 2012: recruiting since February 2012
Contact information Waleed El-Khayat, MD
Faculty of Medicine, Cairo University
Telephone: 23655215
e-mail: Waleed Elkhart@yahoo.com
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Notes
El-Toukhy 2009
Trial name or title TRial of OutPatient HYsteroscopy in in-vitro fertilisation (IVF)- Trophy in IVF
ISRCTN35859078
Methods Multicentre, parallel-group randomised controlled trial
Participants Women 36 years of age or less, undergoing IVF or ICSI with 2 to 4 previous failed fresh embryo transfers and
no submucous or intramural uterine fibroids distorting the uterine cavity or untreated tubal hydrosalpinges
Interventions Outpatient hysteroscopy in the follicular phase of the menstrual cycle where the IVF cycle is due to start,
followed by standard IVF treatment compared to IVF treatment without a prior outpatient hysteroscopy
Outcomes Primary: live birth event per cycle started, measured after 9 months of embryo transfer
Secondary: embryo implantation rate, pregnancy rate per cycle, clinical pregnancy rate per cycle, miscarriage
rate per pregnancy achieved, measured 2 and 4 weeks after embryo transfer
Starting date Current status on 1 November 2012: trial completed; trial results are being processed at present
Contact information Dr Tarek El-Toukhy
Assisted Conception Unit
11th Floor, Tower Wing
Guy’s Hospital
Great Maze Pond, London, United Kingdom
Telephone: +44 (0)20 7188 0497; Fax: +44 (0)20 7188 0490
e-mail: Tarek.El-Toukhy@gstt.nhs.uk
Notes
Maramazi 2012
Trial name or title Effect of hysteroscopy before intra uterine insemination on fertility in infertile couples patients referred to
Imam Khomeini Hospital, Ahwaz IVF
Methods Randomisation: randomised; blinding: not blinded; placebo: not used; assignment: parallel
Participants Infertile patients aged 20 to 40 years who are candidates for IUI with normal hysterosalpingography
Exclusion criterion: ovarian hyperstimulation syndrome in patients suffering complications during surgery
and hysteroscopy
Interventions Intervention group: hysteroscopy
Control group: no hysteroscopy
Outcomes Primary outcome: pregnancy, diagnosed by ultrasound at 2 months after intervention
Secondary outcome: complications of hysteroscopy and treatment side effects of ovulation induction
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Maramazi 2012 (Continued)
Starting date Current status on 1 November 2012: completed; the first author was contacted
Contact information Dr. Farideh Maramazi
Imam Khomeini Hospital - IVF Department
Jundi Shapur University of Medical Sciences, Ahwaz
Telephone: 00986112222114
e-mail: maramazi.f@ajums.ac.ir
Notes
Revel 2011
Trial name or title Safety study of use of hyaluronic acid gel to prevent intrauterine adhesions in hysteroscopic surgery
Methods Single-centre, parallel-group, randomised, single-blind controlled trial
Participants Women 18 years of age or older, undergoing hysteroscopic treatment
Interventions Application of hyaluronic acid gel (study group); the control intervention is not described
Outcomes Patient satisfaction following gel application at 2 months
Starting date Current status on 1 November 2012: not yet recruiting
Contact information Ariel Revel, MD
Hadassah Medical Organization
Telephone: 97226777111 ext 76389
e-mail: ariel2@hadassah.org.il
Notes
Sohrabvand 2012
Trial name or title Evaluation of diagnostic hysteroscopy findings in patients candidate for ART (IVF, ICSI) and its effect on
pregnancy rate compared to control group
Methods Randomisation: randomised; blinding: not blinded; placebo: not used; assignment: parallel; purpose: treat-
ment
Participants Inclusion criteria: hysterosalpingography normal during the past 12 months; normal vaginal ultrasound; age
between 25 and 40 years; absence of abnormal uterine bleeding and no hysteroscopy performed in the last 6
months
Interventions Control group: hysteroscopy is not done
In the intervention group a hysteroscopy is performed; submucosal myoma or polyps 1 cm or larger cervical
or uterine adhesions will be resolved
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Outcomes Primary outcomes: presence of pathology
Secondary outcomes: pregnancy 14 days after embryo transfer
Starting date Current status on 1 November 2012: recruiting since June 2012
Contact information Farnaz Sohrabvand
Vali-e-Asr Reproductive Health & Research Center
Telephone: 00982166939320
e-mail: fsohrabvand@yahoo.com
Notes
ICSI: intracytoplasmic sperm injection
IUI: intrauterine insemination
IVF: in vitro fertilisation
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D A T A A N D A N A L Y S E S
Comparison 1. Operative hysteroscopy versus control in women with otherwise unexplained subfertility and
suspected major uterine cavity abnormalities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical pregnancy 1 94 Odds Ratio (M-H, Fixed, 95% CI) 2.44 [0.97, 6.17]
1.1 Removal of submucous
fibroids only vs regular
fertility-oriented intercourse
1 52 Odds Ratio (M-H, Fixed, 95% CI) 2.04 [0.62, 6.66]
1.2 Removal of mixed
submucous-intramural fibroids
vs regular fertility-oriented
intercourse
1 42 Odds Ratio (M-H, Fixed, 95% CI) 3.24 [0.72, 14.57]
2 Miscarriage 1 94 Odds Ratio (M-H, Fixed, 95% CI) 1.54 [0.47, 5.00]
2.1 Removal of submucous
fibroids only vs regular
fertility-oriented intercourse
1 52 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.27, 5.97]
2.2 Removal of mixed
submucous-intramural fibroids
vs regular fertility-oriented
intercourse
1 42 Odds Ratio (M-H, Fixed, 95% CI) 2.0 [0.32, 12.33]
Comparison 2. Operative hysteroscopy versus control in women undergoing MAR with suspected major uterine
cavity abnormalities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical pregnancy 1 204 Odds Ratio (M-H, Fixed, 95% CI) 4.41 [2.45, 7.96]
1.1 Hysteroscopic
polypectomy vs diagnostic
hysteroscopy and biopsy only
prior to IUI
1 204 Odds Ratio (M-H, Fixed, 95% CI) 4.41 [2.45, 7.96]
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Analysis 1.1. Comparison 1 Operative hysteroscopy versus control in women with otherwise unexplained
subfertility and suspected major uterine cavity abnormalities, Outcome 1 Clinical pregnancy.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 1 Operative hysteroscopy versus control in women with otherwise unexplained subfertility and suspected major uterine cavity abnormalities
Outcome: 1 Clinical pregnancy
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006 13/30 6/22 66.2 % 2.04 [ 0.62, 6.66 ]
Subtotal (95% CI) 30 22 66.2 % 2.04 [ 0.62, 6.66 ]
Total events: 13 (Operative hysteroscopy), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006 8/22 3/20 33.8 % 3.24 [ 0.72, 14.57 ]
Subtotal (95% CI) 22 20 33.8 % 3.24 [ 0.72, 14.57 ]
Total events: 8 (Operative hysteroscopy), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
Total (95% CI) 52 42 100.0 % 2.44 [ 0.97, 6.17 ]
Total events: 21 (Operative hysteroscopy), 9 (Control)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 0.22, df = 1 (P = 0.64), I2 =0.0%
0.01 0.1 1 10 100
Favours intercourse Favours myomectomy
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Analysis 1.2. Comparison 1 Operative hysteroscopy versus control in women with otherwise unexplained
subfertility and suspected major uterine cavity abnormalities, Outcome 2 Miscarriage.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 1 Operative hysteroscopy versus control in women with otherwise unexplained subfertility and suspected major uterine cavity abnormalities
Outcome: 2 Miscarriage
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Removal of submucous fibroids only vs regular fertility-oriented intercourse
Casini 2006 5/30 3/22 62.7 % 1.27 [ 0.27, 5.97 ]
Subtotal (95% CI) 30 22 62.7 % 1.27 [ 0.27, 5.97 ]
Total events: 5 (Operative hysteroscopy), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
2 Removal of mixed submucous-intramural fibroids vs regular fertility-oriented intercourse
Casini 2006 4/22 2/20 37.3 % 2.00 [ 0.32, 12.33 ]
Subtotal (95% CI) 22 20 37.3 % 2.00 [ 0.32, 12.33 ]
Total events: 4 (Operative hysteroscopy), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Total (95% CI) 52 42 100.0 % 1.54 [ 0.47, 5.00 ]
Total events: 9 (Operative hysteroscopy), 5 (Control)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
0.01 0.1 1 10 100
Favours intercourse Favours myomectomy
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Analysis 2.1. Comparison 2 Operative hysteroscopy versus control in women undergoing MAR with
suspected major uterine cavity abnormalities, Outcome 1 Clinical pregnancy.
Review: Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
Comparison: 2 Operative hysteroscopy versus control in women undergoing MAR with suspected major uterine cavity abnormalities
Outcome: 1 Clinical pregnancy
Study or subgroup
Operative
hys-
teroscopy Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hysteroscopic polypectomy vs diagnostic hysteroscopy and biopsy only prior to IUI
P rez-Medina 2005 64/101 29/103 100.0 % 4.41 [ 2.45, 7.96 ]
Total (95% CI) 101 103 100.0 % 4.41 [ 2.45, 7.96 ]
Total events: 64 (Operative hysteroscopy), 29 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.93 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diagnostic only Favours polypectomy
A D D I T I O N A L T A B L E S
Table 1. Effect of polyp size on clinical pregnancy rates in the intervention group
Polyp size Clinical pregnancy1 Clinical pregnancy rate (95% CI)2
< 5 mm 19/25 76% (from 72% to 80%)
5 to 10 mm 18/32 56% (from 53% to 59%)
11 to 20 mm 16/26 61% (from 58% to 65%)
> 20 mm 11/18 61% (from 58% to 64%)
1 Clinical pregnancy is defined by a pregnancy diagnosed by ultrasound visualisation of at least one gestational sac per woman
randomised.
2 No significant difference was found for the clinical pregnancy rates between the 4 subgroups (P = 0.32).
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Table 2. GRADE evidence profile - unexplained subfertility and submucous fibroids
Quality assessment
Submucous fibroids and unexplained subfertility
No of studies Design Limitations Inconsistency Indirectness Imprecision Other considerations
Clinical pregnancy (follow-up 1 year; ultrasound1)
1 RCT Serious2 No serious inconsis-
tency
No serious indirect-
ness
Serious3 Reporting bias4
Miscarriage (follow-up 1 year; ultrasound5)
1 RCT Serious2 No serious inconsis-
tency
No serious indirect-
ness
Serious3 Reporting bias4
1 A clinical pregnancy was defined by the visualisation of an embryo with cardiac activity at six to seven weeks’ gestational age.
2 Unclear allocation concealment.
3 Wide confidence intervals.
4 Unclear selective reporting and unclear whether there is other bias caused by imbalance in the baseline characteristics.
5 Miscarriage was defined by the clinical loss of an intrauterine pregnancy between the 7th and 12th weeks of gestation.
Table 3. GRADE evidence profile - endometrial polyps prior to IUI
Quality assessment
Endometrial polyps prior to gonadotropin and IUI treatment
No of studies Design Limitations Inconsistency Indirectness Imprecision Other considera-
tions
Clinical pregnancy (follow-up 4 IUI cycles; ultrasound1)
1 RCT No serious limita-
tions
No serious incon-
sistency
No serious indi-
rectness
No serious impre-
cision
Reporting bias2
Strong association
3
1 Clinical pregnancy was defined by the presence of at least one gestational sac on ultrasound.
2 There was some potential for reporting bias.
3 Large treatment effect in the absence of plausible confounders.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1 exp Hysteroscopy/ (236)
2 Hysteroscop$.tw. (403)
3 Uteroscop$.tw. (0)
4 endoscop$.tw. (8356)
5 Endoscopy/ (1145)
6 or/1-5 (9009)
7 exp Infertility/ (1486)
8 subfertil$.tw. (128)
9 Infertilit$.tw. (1311)
10 exp Sperm Injections, Intracytoplasmic/ or exp Reproductive Techniques/ or exp Reproductive Techniques, Assisted/ or exp Fertil-
ization in Vitro/ (2521)
11 (IVF or ICSI).tw. (2158)
12 artificial insemination.tw. (53)
13 assisted conception.tw. (56)
14 exp Myoma/ or exp Leiomyoma/ (353)
15 (myoma or myomectomy).tw. (273)
16 septate uterus.tw. (9)
17 polypectomy.tw. (128)
18 adhesiolysis.tw. (47)
19 exp Tissue Adhesions/ (224)
20 (remov$ adj2 adhesion).tw. (4)
21 polyp$.tw. (2523)
22 uterine septa.tw. (7)
23 uterine septum.tw. (9)
24 synechiotomy.tw. (1)
25 Leiomyoma$.tw. (190)
26 uterine malformation$.tw. (6)
27 (Uter$ adj4 Neoplasm$).tw. (1)
28 (uter$ adj4 abnormalit$).tw. (43)
29 fibroid$.tw. (210)
30 or/7-29 (7836)
31 6 and 30 (460)
32 limit 31 to yr=“2011 -Current” (22)
Database: Cochrane Central Register of Controlled Trials (CENTRAL) July 2012.
Appendix 2. Cochrane Menstrual Disorders and Subfertility Group Specialised Register search
strategy
Keywords CONTAINS “hysteroscopic ”or “hysteroscopy”or “hysteroscope”or “endoscopy” or Title CONTAINS “hysteroscopic ”or
“hysteroscopy”or “hysteroscope”or “endoscopy”
AND
Keywords CONTAINS “subfertility”or “subfertility-Female”or “infertility” or “IVF” or “ICSI” or “IUI”or “in vitro fertilisation”
or “in vitro fertilization” or “Intrauterine Insemination” or “artificial insemination” or “assisted conception” or “assisted reproduc-
tion techniques” or “ embryo transfer” or “zygote intrafallopian transfer” or “myoma” or “myomas” or “myomectomy” or “septate
uterus”or “polypectomy” or“polyp removal” or “polyps”or “adhesiolysis”or “adhesion” or“adhesions” or“synechiotomy” or“Leiomyoma”
or“leiomyomata” or“fibroids” or“Asherman’s Syndrome”or “uterine septa”or “uterine septum” or“uterine disease”or “uterine leiomy-
omas” or“uterine malformation” or“Uterine Neoplasms”or “uterine polyps”
155 records
Most recent update 6 August 2012.
53Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. MEDLINE through PubMed search strategy
(“Hysteroscopy”[MeSH] OR Uterine Endoscop*[All Fields] OR Uteroscop*[All Fields] OR Hysteroscopic Surg*[All Fields] OR (hys-
teroscopic[All Fields] AND (polypectom*[All Fields] OR polyp removal*[All Fields] OR myomectom*[All Fields] OR synechioly-
sis[All Fields] OR synechiotomy[All Fields] OR adhesiolysis[All Fields] OR metroplast*[All Fields] OR septoplast*[All Fields] OR
septum resection*[All Fields]))) AND (Subfertility[tiab] OR “Infertility, Female”[MeSH] OR (female[tiab] AND (Infertility[tiab] OR
Sterility[tiab]))) AND (((“Endometrium”[MeSH] OR Endometri*[All Fields]) AND (polyp[All Fields] OR polyps[All Fields])) OR
“Leiomyoma”[MeSH] OR Leiomyoma[All Fields] OR Leiomyomas[All Fields] OR Fibromyoma[All Fields] OR Fibromyomas[All
Fields] OR Fibroid[All Fields] OR Fibroids[All Fields] OR fibromas[All Fields] OR Myoma[All Fields] OR Myomas[All Fields] OR
((Synechiae[All Fields] AND ((Intrauterine[All Fields] OR uterine[All Fields]) AND adhesion*)) OR “Asherman Syndrome”[All Fields]
OR “Asherman’s Syndrome”[All Fields] OR “Ashermans Syndrome”[All Fields] OR ((septa[All Fields] OR septum[All Fields]) AND
(uterine[All Fields] OR intrauterine[All Fields])) OR “Uterine Diseases”[MeSH] OR “Uterine Neoplasms”[MeSH] OR ((uterine[All
Fields] OR intrauterine[All Fields]) AND “Congenital Abnormalities”[MeSH]) OR “Fertilization in Vitro”[MeSH] OR (Fertiliza-
tion[All Fields] AND “in Vitro”[All Fields]) OR IVF[All Fields] OR ICSI[All Fields] OR “Reproductive Techniques”[MeSH] OR
“Embryo Transfer”[MeSH] OR “Zygote Intrafallopian Transfer”[MeSH] OR “Insemination, Artificial”[MeSH] OR ((intrauterine OR
artificial) AND insemination[All Fields]))) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab]
OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh])
#1 (“Hysteroscopy”[MeSH] OR Uterine Endoscop*[All Fields] OR Uteroscop*[All Fields] OR Hysteroscopic Surg*[All Fields] OR
(hysteroscopic[All Fields] AND (polypectom*[All Fields] OR polyp removal*[All Fields] OR myomectom*[All Fields] OR synechiol-
ysis[All Fields] OR synechiotomy[All Fields] OR adhesiolysis[All Fields] OR metroplast*[All Fields] OR septoplast*[All Fields] OR
septum resection*[All Fields]))) (3493)
#2 (Subfertility[tiab] OR “Infertility, Female”[MeSH] OR (female[tiab] AND (Infertility[tiab] OR Sterility[tiab]))) (27267)
#3 (((“Endometrium”[MeSH] OR Endometri*[All Fields]) AND (polyp[All Fields] OR polyps[All Fields])) OR “Leiomyoma”[MeSH]
OR Leiomyoma[All Fields] OR Leiomyomas[All Fields] OR Fibromyoma[All Fields] OR Fibromyomas[All Fields] OR Fibroid[All
Fields] OR Fibroids[All Fields] OR fibromas[All Fields] OR Myoma[All Fields] OR Myomas[All Fields] OR ((Synechiae[All Fields]
AND ((Intrauterine[All Fields] OR uterine[All Fields]) AND adhesion*)) OR “Asherman Syndrome”[All Fields] OR “Asherman’s
Syndrome”[All Fields] OR “Ashermans Syndrome”[All Fields] OR ((septa[All Fields] OR septum[All Fields]) AND (uterine[All Fields]
OR intrauterine[All Fields])) OR “Uterine Diseases”[MeSH] OR “Uterine Neoplasms”[MeSH] OR ((uterine[All Fields] OR intrauter-
ine[All Fields]) AND “Congenital Abnormalities”[MeSH]) OR “Fertilization in Vitro”[MeSH] OR (Fertilization[All Fields] AND “in
Vitro”[All Fields]) OR IVF[All Fields] OR ICSI[All Fields] OR “Reproductive Techniques”[MeSH] OR “Embryo Transfer”[MeSH]
OR “Zygote Intrafallopian Transfer”[MeSH] OR “Insemination, Artificial”[MeSH] OR ((intrauterine OR artificial) AND insemina-
tion[All Fields]))) (278308)
#4 (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR
randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT humans[mh]) (2621133)
#5 1 AND 2 AND 3 AND 4 (69)
Most recent update: 27 October 2012.
Appendix 4. EMBASE through Embase.com search strategy
’hysteroscopy’/expOR ’hysteroscopy’OR (’uterine’ OR ’uterine’/expORuterine AND endoscop* AND [embase]/lim)OR (uteroscop*
AND [embase]/lim)OR (hysteroscopicNEAR/1 surg* AND [embase]/lim)OR (’myomectomy’/expOR ’myomectomy’OR (myomec-
tom* AND [embase]/lim) OR (polypectom* AND [embase]/lim) OR (’polyp’/exp OR polyp AND removal) OR (synechiolysis AND
[embase]/lim) OR synechiotomy OR (adhesiolysis AND [embase]/lim) OR (metroplasty AND [embase]/lim) OR (septoplast* AND
[embase]/lim) OR (septum NEAR/1 resection* AND [embase]/lim) AND hysteroscopic AND [embase]/lim) AND (’female infertil-
ity’/exp OR ’female infertility’ OR (female:ab,ti AND (infertility:ab,ti OR sterility:ab,ti) AND [embase]/lim) OR (female:ab,ti AND
(subfertility:ab,ti OR sterility:ab,ti) AND [embase]/lim)) AND (endometri* NEAR/1 polyp* AND [embase]/lim OR (’endometrium’/
exp OR ’endometrium’ AND polyp* AND [embase]/lim) OR ’leiomyoma’/exp OR ’leiomyoma’ OR (leiomyoma* AND [embase]/
lim) OR (fibromyoma* AND [embase]/lim) OR (fibroid* AND [embase]/lim) OR (fibroma* AND [embase]/lim) OR (myoma* AND
[embase]/lim) OR (synechiae AND (intrauterine OR uterine) NEAR/1 adhesion* AND [embase]/lim) OR ’uterus synechia’/exp OR
’uterus synechia’ OR (’asherman syndrome’/exp OR ’asherman syndrome’ OR ’ashermans syndrome’ AND [embase]/lim) OR (asher-
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man* AND (’syndrome’OR ’syndrome’/expOR syndrome) AND [embase]/lim)OR (’septa’OR ’septa’/expOR septaOR septum AND
(’uterine’ OR ’uterine’/exp OR uterine OR ’intrauterine’ OR ’intrauterine’/exp OR intrauterine) AND [embase]/lim) OR ’uterine
diseases’/exp OR ’uterine diseases’ OR ’uterine neoplasms’/exp OR ’uterine neoplasms’ OR ’congenital uterus malformation’/exp OR
’congenital uterus malformation’ OR ’fertilization in vitro’/exp OR ’fertilization in vitro’ OR (’fertilization’ OR ’fertilization’/exp OR
fertilization AND (’in vitro’/exp OR ’in vitro’) OR ivf AND [embase]/lim) OR ’icsi’ OR ’icsi’/exp OR icsi OR ’reproductive techniques
assisted’/exp OR ’reproductive techniques assisted’ OR ’embryo transfer’/exp OR ’embryo transfer’ OR (’zygote’ OR ’zygote’/exp OR
zygote AND intrafallopian AND transfer) OR ’artificial insemination’/exp OR ’artificial insemination’ OR ((intrauterine OR artificial)
NEAR/1 insemination AND [embase]/lim)) AND (’clinical trial’/exp OR ’clinical trial’ OR ’randomized controlled trial’/exp OR
’randomized controlled trial’ OR ’randomization’/exp OR ’randomization’ OR ’single blind procedure’/exp OR ’single blind procedure’
OR ’double blind procedure’/exp OR ’double blind procedure’ OR ’crossover procedure’/exp OR ’crossover procedure’ OR ’placebo’/
exp OR ’placebo’ OR (randomi?ed AND controlled AND trial* AND [embase]/lim) OR (rct AND [embase]/lim) OR (’random
allocation’/exp OR ’random allocation’ AND [embase]/lim) OR (’randomly allocated’ AND [embase]/lim) OR (’allocated randomly’
AND [embase]/lim)OR (allocated NEAR/2 random AND [embase]/lim) OR (’single blind$’ AND [embase]/lim) OR (’double blind$’
AND [embase]/lim) OR ((treble OR triple) NEAR/2 blind$ AND [embase]/lim) OR (placebo$ AND [embase]/lim) OR ’prospective
study’/exp OR ’prospective study’) NOT (’case study’/exp OR ’case study’ OR ’case report’/exp OR ’case report’ OR ’abstract report’/
exp OR ’abstract report’ OR ’letter’/exp OR ’letter’) NOT (’animal’/exp OR ’animal’ NOT (’human’/exp OR ’human’))
1 ’hysteroscopy’/exp OR ’hysteroscopy’ (7410 )
2 ’uterine’ OR ’uterine’/exp OR uterine AND endoscop* AND [embase]/lim (20736)
3 uteroscop* AND [embase]/lim (18)
4 hysteroscopic NEAR/1 surg* AND [embase]/lim (319)
5 ’myomectomy’/exp OR ’myomectomy’ (3643)
6 myomectom* AND [embase]/lim (3252)
7 polypectom* AND [embase]/lim (6659)
8 ’polyp’/exp OR polyp AND removal (1924)
9 synechiolysis AND [embase]/lim (50)
10 synechiotomy (7)
11 adhesiolysis AND [embase]/lim (1138)
12 metroplasty AND [embase]/lim (337)
13 septoplast* AND [embase]/lim (919)
14 septum NEAR/1 resection* AND [embase]/lim (75)
15 OR/ 5-14 (13953 )
16 hysteroscopic AND [embase]/lim (2720)
17 15 AND 16 (777)
18 1 OR 2 OR 3 OR 4 OR 17 (23782)
19 ’female infertility’/exp OR ’female infertility’(34316)
20 female:ab,ti AND (infertility:ab,ti OR sterility:ab,ti) AND [embase]/lim (5400)
21 female:ab,ti AND (subfertility:ab,ti OR sterility:ab,ti) AND [embase]/lim (1321)
22 19 OR 20 OR 21 (37525)
23 endometri* NEAR/1 polyp* AND [embase]/lim (1969)
24 ’endometrium’/exp OR ’endometrium’ (72576)
25 polyp* AND [embase]/lim (337581)
26 24 AND 25 (3631)
27 23 OR 26 (3770)
28 ’leiomyoma’/exp OR ’leiomyoma’ (16602)
29 leiomyoma* AND [embase]/lim(11724)
30 28 OR 29 (18992 )
31 fibromyoma* AND [embase]/lim (250)
32 fibroid* AND [embase]/lim (4397)
33 fibroma* AND [embase]/lim (10749)
34 myoma* AND [embase]/lim (10547)
35 synechiae AND (intrauterine OR uterine) NEAR/1 adhesion* AND [embase]/lim (28)
36 ’uterus synechia’/exp OR ’uterus synechia’ (736)
37 ’asherman syndrome’/exp OR ’asherman syndrome’ OR ’ashermans syndrome’ AND [embase]/lim (741)
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38 asherman* AND (’syndrome’ OR ’syndrome’/exp OR syndrome) AND [embase]/lim (205)
39 ’septa’ OR ’septa’/exp OR septa OR septum AND (’uterine’ OR ’uterine’/exp OR uterine OR ’intrauterine’ OR ’intrauterine’/exp
OR intrauterine) AND [embase]/lim (1398 )
40 ’uterine diseases’/exp OR ’uterine diseases’ (177248)
41 ’uterine neoplasms’/exp OR ’uterine neoplasms’ (98381)
42 ’congenital uterus malformation’/exp OR ’congenital uterus malformation’ (3598)
43 ’fertilization in vitro’/exp OR ’fertilization in vitro’ (35590)
44 ’fertilization’ OR ’fertilization’/exp OR fertilization AND (’in vitro’/exp OR ’in vitro’) OR ivf AND [embase]/lim (46128)
45 ’icsi’ OR ’icsi’/exp OR icsi (12561)
46 ’reproductive techniques assisted’/exp OR ’reproductive techniques assisted’ (71428)
47 ’embryo transfer’/exp OR ’embryo transfer’ (20233)
48 ’zygote’/exp OR zygote AND intrafallopian AND transfer (135)
49 ’artificial insemination’/exp OR ’artificial insemination’ (13789)
50 (intrauterine OR artificial) NEAR/1 insemination AND [embase]/lim (8647)
51 27 OR 30-50 (277312)
52 18 AND 22 AND 51 (1335)
53 ’clinical trial’/exp OR ’clinical trial’ (1051671)
54 ’randomized controlled trial’/exp OR ’randomized controlled trial’ (354684)
55 ’randomization’/exp OR ’randomization’ (71847)
56 ’single blind procedure’/exp OR ’single blind procedure’ (15974)
57 ’double blind procedure’/exp OR ’double blind procedure’ (111202)
58 ’crossover procedure’/exp OR ’crossover procedure’ (35533)
59 ’placebo’/exp OR ’placebo’ (297437)
60 randomi?ed AND controlled AND trial* AND [embase]/lim (319263)
61 rct AND [embase]/lim (10028)
62 ’random allocation’/exp OR ’random allocation’ AND [embase]/lim (34639)
63 ’randomly allocated’ AND [embase]/lim (14933)
64 ’allocated randomly’ AND [embase]/lim (1585)
65 allocated NEAR/2 random AND [embase]/lim (683)
66 ’single blind$’ AND [embase]/lim (17490)
67 ’double blind$’ AND [embase]/lim (145208)
68 (treble OR triple) NEAR/2 blind$ AND [embase]/lim (261)
69 placebo$ AND [embase]/lim (267409)
70 ’prospective study’/exp OR ’prospective study’ (263707)
71 OR/ 53-70 (1447482)
72 ’case study’/exp OR ’case study’ (67892)
73 ’case report’/exp OR ’case report’ AND [embase]/lim (1307072)
74 ’abstract report’/exp OR ’abstract report’ (89566)
75 ’letter’/exp OR ’letter’(855918)
76 OR/ 72-75 (2186940)
77 71 NOT 76 (1388842)
78 ’animal’/exp OR ’animal’ (18459336)
79 ’human’/exp OR ’human’ (17532043)
80 78 NOT 79 (2128576)
81 77 NOT 80 (1358768)
82 52 AND 81 (248)
Most recent update 27 October 2012.
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Appendix 5. CINAHL through EBSCOHOST search strategy
S1 TX hysteroscopy (345)
S2 TX uterine endoscop* (4)
S3 TX uteroscop* (0)
S4 TX hysteroscopic surg* (24)
S5 TX hysteroscopic polypectom* (4)
S6 “hysteroscopic polyp removal*” (16) Smart Text searching
S7 TX hysteroscopic myomectom* (11)
S8 TX hysteroscopic adhesiolys* (2)
S9 TX hysteroscopic synechiolys* (0)
S10 TX hysteroscopic synechiotomy (0) Smart Text searching
S11 TX hysteroscopic metroplast* (5)
S12 TX hysteroscopic septoplast* (0) Smart Text searching
S13 TX hysteroscopic septum resection (24) Smart Text searching
S14 TX hysteroscopic sept* resection (1)
S15 TX subfertility (259)
S16 TX infertility (4418)
S17 TX sterility (328)
S18 TX female (667400)
S19 TX endometri* polyp* (69)
S20 TX leiomyoma* (1078)
S21 TX fibromyoma* (5)
S22 TX fibroid* (512)
S23 TX fibroma* (343)
S24 TX myoma* (147)
S25 TX “synechia*” (67)
S26 TX intrauterine adhesion* (8)
S27 TX uterine adhesion* (15)
S28 TX Asherman* syndrome (7)
S29 TX uterine sept* (12)
S30 TX intrauterine sept* (6)
S31 TX “septate uterus” (15)
S32 TX uterine diseases (367)
S33 TX uterine neoplasm* (863)
S34 TX uterine congenital abnormalit* (1)
S35 TX uterine congenital abnormalities (1)
S36 TX uterine malformation* (21)
S37 TX in vitro fertilisation (187)
S38 TX in vitro fertilization (1821)
S39 TX IVF (690)
S40 TX assisted reprod* (768)
S41 TX ICSI (128)
S42 TX embryo transfer(402)
S43 TX zygote intrafallopian transfer (8)
S44 TX artificial insemination (300)
S45 TX intrauterine insemination (80)
S46 TX IUI (40)
S47 (MH “Clinical Trials”) (75886)
S48 PT clinical trial* (51716)
S49 (MH “Randomized Controlled Trials”) (11719)
S50 PT randomized controlled trial* (11680)
S51 “randomised controlled trial” (3920)
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S52 PT randomised controlled trial* (198)
S53 (MH “Random Assignment”) (28382)
S54 TX Randomi*ation (3032)
S55 TX single blind* (6185)
S56 TX double blind* (532573)
S57 TX triple blind* (93)
S58 TX treble blind* (0) Smart Text searching
S59 TX Placebo* (23319)
S60 TX prospective stud* (145823)
S61 OR/S47-60 (729472)
S62 OR/S1-14 (359)
S63 OR/S15-17 (4864)
S64 S18 AND S63 (3060)
S65 0R/S19-46 (5398)
S66 S61 and S62 and S64 and S65 (9)
Most recent update: 28 October 2012.
Appendix 6. ISI Web of Science search strategy
TS=((((Hysteroscopy OR Uterine Endoscop* OR Uteroscop* OR Hysteroscopic Surg* OR (hysteroscopic AND (polypectom* OR
myomectom* OR synechiolysis OR adhesiolysis OR metroplast* OR septoplast* OR septum resection*))) AND (female AND (Sub-
fertility OR Infertility OR Sterility)) AND ((Endometri* AND (polyp OR polyps)) OR Leiomyoma* OR Fibromyoma* OR Fibroid*
OR fibromas OR Myoma* OR Synechiae OR ((Intrauterine OR uterine) AND adhesion*) OR (Asherman* AND Syndrome*) OR
((septa OR septum) AND (uterine OR intrauterine)) OR uterine diseases OR uterine neoplasms OR ((uterine OR intrauterine) AND
(congenital abnormalities)) OR (Fertilization SAME “in Vitro”) OR IVF OR ICSI OR reproductive techniques OR embryo transfer
Or zygote intrafallopian transfer OR ((intrauterine OR artificial) AND insemination)))))
60 records time span = all years. Databases = SCI-EXPANDED, CPCI-S.
Most recent update 27 October 2012.
Appendix 7. Items of data extraction
1. Source
1. Study ID
2. Report Id
3. Review author ID
4. Citation and contact details
2. Eligibility
1. Confirm eligibility for review
2. Reason for exclusion
3. Trial characteristics
1.Study design
• Random sequence generation
• Patient recruitment
• Patient in- and exclusion criteria
• Allocation concealment
58Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Completeness of outcome data
• Selective outcome reporting
• Other potential sources of bias
2. Follow-up
• Duration of follow-up
• Type of follow-up
3. Size of study
• Number of women recruited
• Number of women randomised
• Number of women excluded
• Number of women withdrawn and lost to follow-up
• Number of women analysed
4. Study setting
• Single-centre or multicentre
• Location
• Timing and duration
5. Diagnostic criteria
• Screening by TVS
• Screening by HSG
• Screening by TVS and HSG
• Screening by other ultrasound diagnostic procedures, e.g. SIS or GIS
• Screening by hysteroscopy
• Diagnosis confirmed by hysteroscopy and biopsy
4. Characteristics of the study participants
1. Baseline characteristics
• Age
• Primary or secondary subfertility
• Duration of subfertility
• Diagnostic work-up: baseline FSH, semen analysis, diagnosis of tubal pathology, confirmatory test of ovulation
• Other contributory causes to subfertility than uterine factor
• Previous treatments - IVF, IUI or other treatments
2. Treatment characteristics
• IUI natural cycle
• IUI controlled ovarian stimulation with anti-oestrogens or gonadotropins
• IVF protocol and number of embryos transferred
• ICSI protocol and number of embryos transferred
• detailed description of the hysteroscopic procedure
5. Interventions
• Total number of intervention groups
• Absence of other interventions in the treatment and control group
For each intervention and comparison group of interest:
• Specific intervention
• Intervention details
• Timing of the intervention
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6. Outcomes
• Outcomes and time points collected
• Outcomes and time points reported
Definition and unit of measurement for each of the following outcomes:
Primary outcome:
• Live birth delivery rate
• Hysteroscopy complication rate
Secondary outcome:
• Ongoing pregnancy rate
• Clinical pregnancy with fetal heart beat
• Clinical pregnancy rate
• Miscarriage rate
For each outcome of interest:
• Sample size
• Missing participants
• Summary data for each intervention group in 2 x 2 table
• Estimate of effect with 95% CI
• Subgroup analyses
7. Miscellaneous
• Funding source
• Key conclusions of the study authors
• Miscellaneous comments from the study authors
• References to other relevant studies
• Correspondence required
• Miscellaneous comments by the review authors
C O N T R I B U T I O N S O F A U T H O R S
JB co-ordinated the writing of the protocol and review.
JK co-authored the protocol for the background section and searched the literature.
FB and TD independently assessed the retrieved published reports for inclusion of potentially eligible studies.
SW independently extracted study data.
BWM gave advice on review methodology and content and critically appraised the Cochrane review.
D E C L A R A T I O N S O F I N T E R E S T
FB and JK (principal investigator) and BWM (co-investigator) are at present involved in the ’inSIGHT trial’ (SIGnificance of Routine
Hysteroscopy Prior to a First ’in Vitro Fertilization’ Treatment Cycle: NCT 01242852), which is financially supported by ZonMw, a
Dutch government operated consortium responsible for granting funds in the field of clinical practice research. This study is at present
in the recruitment phase.
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S O U R C E S O F S U P P O R T
Internal sources
• CEBAM, Belgium.
Research grant was obtained through CEBAM, the Centre for Evidence-based Medicine, Belgian Branch of the Cochrane
Collaboration
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. As a result of further peer review, the objectives of the review have been rephrased. The descriptions in the Types of interventions
and Data synthesis sections were modified accordingly. For both comparisons we made a stratification according to the types of
uterine pathology; for the second comparison we made a clear distinction between IUI, IVF or ICSI.
2. A ’Summary of findings’ table using the GRADE approach has been added.
3. In the Assessment of risk of bias in included studies section of the review, the items ’blinding of participants and personnel’ and
’blinding of outcome assessors’ were reinserted as requested by the editorial reviewers.
4. In the Assessment of heterogeneity section of the review we have added the Q-statistic.
5. In the Subgroup analysis and investigation of heterogeneity section of the review we planned to conduct a further subgroup
analysis based on the women’s age.
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